Modulation of Human Papilloma Virus transcription by
Jagged1 in cervical cancer cell lines
Master's thesis in Cell biology

Sara Koivuluoma
40852
Supervisor: Prof. Cecilia Sahlgren
Practical supervisor: Elenaé Vázquez-Ulloa, Postdoc
Utbildningsprogrammet i cellbiologi,
Institutionen för biovetenskaper,
Åbo Akademi 2021

Abstract
The Human Papilloma Virus (HPV) is a common sexually transmitted pathogen and
the etiological agent for developing cervical cancer (CC). From the high-risk HPVs
(hr-HPV), types 16 and 18 are the most prevalent ones. HPV carcinogenesis is driven
by the oncoproteins E5, E6, and E7. These proteins' expression is under transcriptional
regulation by the HPVs' Long Control Region (LCR). The LCR harbor binding sites
for different transcription factors such as Activator Protein 1 (AP-1). The Jagged1
(JAG1) protein is a well-known Notch pathway ligand. Proteolytic processing of
JAG1 leads to the release of its intracellular domain (JICD), which potentially could
be modulating AP-1 activity.
Here we show that JAG1 is processed in CC-derived cell lines. The overexpression of
JAG1 and JICD modulates the HPV16 and HPV18 LCRs in different cervical cell
lines. Moreover, we show for the first time that JAG1 can bind to c-Jun, which forms
part of the AP-1 complex. Collectively, the results show that JAG1 is involved in
controlling the transcription of HPV in cervical cancer through the modulation of the
AP-1 complex.

Keywords: Human Papilloma Virus (HPV), Cervical Cancer (CC), Jagged1 (JAG1),
Jagged1 Intracellular Doman (JICD), Activator protein-1 (AP-1)

Table of contents
1. Introduction and background .................................................................................................... 1
1.1 Cervical cancer (CC) ..................................................................................................................... 1
1.2 Human Papilloma Virus (HPV) ..................................................................................................... 2
1.3 The HPV Long Coding Region (LCR) ............................................................................................. 3
1.5 The Jagged1 protein (JAG1) ......................................................................................................... 7
2. Objectives ............................................................................................................................... 10
3. Materials and methods ........................................................................................................... 11
3.1 Cell culture ................................................................................................................................. 11
3.2 Protein extraction and quantification........................................................................................ 11
3.3 SDS-PAGE ................................................................................................................................... 13
3.3.1 Western blot ........................................................................................................................... 14
3.3.2 Immunoblotting ...................................................................................................................... 15
3.4. Cloning ...................................................................................................................................... 16
3.4.1 PCR.......................................................................................................................................... 17
3.4.2 Plasmid and insert digestion................................................................................................... 19
3.4.3 Visualization of the DNA fragments ....................................................................................... 19
3.4.4 Gel excision of DNA fragments ............................................................................................... 19
3.4.5. Ligation of the Plasmid and the DNA fragment ..................................................................... 20
3.4.6 Transformation ....................................................................................................................... 20
3.4.7 Plasmid DNA isolation (Maxiprep).......................................................................................... 21
3.5. Cell transfection ........................................................................................................................ 22
3.6. Renilla Luciferase Reporter Assay ............................................................................................. 23
3.7. Proliferation assays .................................................................................................................. 24
3.7.1 Colorimetric cell viability (WST-8) assay ................................................................................. 24
3.8. Co-Immunoprecipitation........................................................................................................... 25
4. Results .................................................................................................................................... 26
4.1 JAG1 is processed in CC cell lines ............................................................................................... 26
4.2 JAG1 is cleaved by γ-secretase in CC cells .................................................................................. 27
4.3 Cloning of the intracellular domain of JAG1 .............................................................................. 28
4.4 JAG1 and JICD modulate the activity of the HPV 16 and HPV18 LCR......................................... 30
4.5 The modulation of the LCR by JAG1 and JICD is dose-dependent .............................................. 34
4.6 The modulation of the HPV LCR in Caski cells is dependent on AP-1 activity ............................ 36
4.7 CC cells express different protein levels of the AP-1 transcription factor components ............. 39
4.8 JAG1 binds to c-Jun .................................................................................................................... 40

4.9.1 JAG1 binds to c-Jun in an overexpressed system .................................................................... 42
5. Discussion ............................................................................................................................... 47
5.1 JAG1 is processed in CC cells ...................................................................................................... 48
5.2 Processing of JAG1 in CC cells by γ-secretase ............................................................................ 50
5.3 Cloning of the intracellular domain of JAG1 .............................................................................. 51
5.4 JAG1 and JICD modulates the activity of LCR in HPV ................................................................. 52
5.5 The modulation of the LCR by JAG1 and JICD is dose-dependent .............................................. 54
5.6 Modulation of LCR is dependent on AP-1 activity in Caski cells ................................................. 55
5.7 CC cells express different protein levels of the AP-1 transcription factor components ............. 57
5.8 JAG1 binds to c-Jun in Caski cells ............................................................................................... 58
5.9 JICD decrease the proliferation of Caski and Hela cells ............................................................. 58
5.10 Concluding summary ............................................................................................................... 59
6. References: ............................................................................................................................. 60
7. Appendices ............................................................................................................................. 66
8. Svensk sammanfattning .......................................................................................................... 68
Introduktion ............................................................................................................................... 68
Material och metoder ................................................................................................................. 70
Kloning ............................................................................................................................................. 70
Tranfektion ...................................................................................................................................... 71
Western blottning (WB)................................................................................................................... 72
Renilla Luciferas reporteranalys ...................................................................................................... 72
Koimmunoprecipitering (IP)............................................................................................................. 73
Resultat och diskussion............................................................................................................... 75
JAG1 processeras i livmoderhalscancer celler ................................................................................. 76
JAG1 klyvs av γ-sekretas i livmoderhalscancer celler....................................................................... 77
Kloning av den intracellulära domänen för JAG1 ............................................................................ 77
JAG1 och JICD modulerar aktiviteten för LCR i HPV ......................................................................... 78
Moduleringen av LCR med JAG1 och JICD är dosberoende ............................................................. 79
Moduleringen av HPV LCR i Caski-celler är beroende av AP-1-aktivitet .......................................... 79
AP-1-transkriptionsfaktorkomplexblottar i livmoderhalscancer-celler............................................ 80
JICD minskar proliferation av Caski- och Hela-celler ....................................................................... 81

Abbreviations
CC

Cervical cancer

HPV

Human Papilloma Virus

ISCC

Invasive squamous cell carcinomas

TZ

Transformation Zone

CIN

Cervical Intraepithelial Neoplasia

HR

High-risk

LR

Low-risk

LCR

Long control region

ICD

Intracellular domain

ECD

Extracellular domain

AP-1

Activator Protein-1

NICD

Notch Intracellular Domain

JICD

Jagged Intracellular Domain

1. Introduction and background
1.1 Cervical cancer (CC)
Cancer is a group of diseases characterized by irregular cell growth. When the disease
progress to malignant disease, cancer cells invade and spread to other location of the
body from the primary tumor. Cancer is not an infectious disease in itself, and the
majority of the cases do not have any infectious traces. However, 15% of human
cancers are caused by mechanisms involving viruses, bacteria, or parasites (Alberts,
2013). Cervical Cancer (CC) occurs due to the persistent infection with Human
Papilloma Virus (HPV), a sexually transmitted pathogen. HPV infection is not enough
for CC development, and other cofactors are needed, e.g., other transmittable
infections, which lower the immune status (Arbyn et al., 2020).
CC is the fourth most common cancer type in women worldwide (Arbyn et al., 2020).
In 2018, there were 570 000 cases of CC and 310 000 deaths globally. In Finland, CC
is the third most common of the gynecologic cancers, with 150-175 cases diagnosed
yearly, and it is most commonly discovered in women aged 30-39 (Duodecim, 2020).
The cervix is comprised of two different tissue; a squamous epithelium which forms
the exocervix; and the endocervix which is lined by mucous-producing columnar cells
(Burd, 2003). Thus, CC is histologically divided into two main sub-categories:
Invasive squamous cell carcinomas (ISCC), which are more common and consist of
85-90% of all CC cases, and adenocarcinomas, which are less common and comprise
10-15% of the cases (Tripathi et al., 2018).
The HPV infects the cervix's stratified squamous epithelia through microtraumas
(Ribeiro et al., 2018). Viruses infect the cervix's basal layer in a mucosa ring called
the transformation zone (TZ), which causes deregulated cell proliferation (Schiffman
et al., 2007). The TZ is located between the endocervix and the ectocervix. It consists
of mature squamous epithelial cells which mature from sub-columnar cells; this
process is called metaplasia. In normal conditions, the cells are in a G1 (growth 1)
phase. They sustain normal cellular functions in this phase. If and when new cells are
needed to maintain tissue homeostasis, the cells exit the G1 stage and undergo cell
division to produce new cells. If the cells are infected with HPV, they can be forced

1

out of the G1 phase, and new cells are dividing faster than the body needs (Burd,
2003).
Cervical carcinogenesis caused by HPV is a multistep process divided into three stages
that also characterize the disease’s severity. The Cervical Intraepithelial Neoplasia
(CIN) begins at the TZ's basal layer in the immature squamous epithelium (Schiffman
et al., 2007). CIN is denoted as grade 1 to 3, (figure 1) depending on how much of the
epithelium is affected. The carcinoma in situ affects the organization of the whole
epithelium except the basal membrane. The basal membrane is disrupted in the
invasive carcinoma (ICC) stage (Schiffman et al., 2007).

Figure 1. Pre-cancer and cancer progression in CC. The different stages of the transformation of the
cervical epithelial cells from normal squamous epithelial cells to invasive carcinoma ( J.O'Leary et al.,
2018)

1.2 Human Papilloma Virus (HPV)
The HPV is associated with many types of cancer, including cervical, anal, penile,
vaginal, vulvar, and oropharyngeal cancer. Other lesions that can occur due to
infection from HPV are warts on different parts of the body (Burd, 2003). The HPVs
are divided into high- and low-risk (hr & lr) types depending on their abilities to cause
cancer (Ribeiro et al., 2018). Hr-variants, such as HPV16 and HPV18, are accountable

2

for about 55% of ISCC. Meanwhile, lr-variants such as HPV6 and HPV11 are
responsible for over 90% of genital wart occurrence (Ribeiro et al., 2018).
More than 100 types of HPV have
been identified, and about 30 of
them are associated with genital
tract lesions (Ottinger et al., 2009).
Papillomaviruses (PVs) belong to
the non-enveloped viruses that have
circular,

double-stranded

DNA.

Their genome contains about 8000
base pairs (bp)(Ribeiro et al., 2018).
It is divided into three regions: The
long control region (LCR), the early
(E), and the late expression (L)
regions (figure 2). The E1 and E2
gene

products

are

essential

regulators of the transcription of the
viral genes; E4, E5, E6, and E7. L1
and L2 genes are translated into
viral capsid proteins (Chakravorty
& Sugden, 2018).
HPV carcinogenesis is mainly caused by the E6 and E7 oncoproteins. When episomal
HPV is integrated into the host genome, the expression of oncoproteins E6 and E7
increases and by forming complexes with the tumor suppressors p53 and pRB the virus
is able to inhibit the normal function of the tumor suppressors, which leads to cellular
transformation (Organista-Nava et al., 2019). Thus, the regulation of viral oncogenes
is essential for tumor initiation.

1.3 The HPV Long Coding Region (LCR)
The LCR is located between the L1 and E6 genes (figure 2), and it comprises around
10% of the viral genome. Different viral and host proteins can bind to the LCR and
either activate or suppress viral transcription. The transcription factor- Activator
3

Protein-1 complex (AP-1) is a transcription factor involved in many biological
processes

(Talora et al., 2002). The AP-1 complex is usually consisting of a

heterodimer with c-Jun and either c-Fos or c-Fra proteins. The complex can also be a
homodimer consisting of only c-Jun proteins. (Garces de Los Fayos Alonso et al.,
2018). The LCRs from different viral types differ in the number of binding sites for
the AP-1 complex (figure 3). The HPV16 LCR has four binding sites (O’Connor et
al., 1996); meanwhile, the HPV18 LCR only has two AP-1 binding sites (Steger &
Corbach, 1997).

Figure 3. The LCR's of HPV16 and HPV18. A. The LCR of HPV16 is divided into three segments,
the 5' segment, the central segment, and the 3' segment. In the central segments, the majority of the
transcription factor binding sites are localized. The four AP-1 binding sites are indicated. B. A
schematic overview of the LCR of HPV18. The locations of the 2 binding sites for AP-1 are shown.
The image is inspired by (O’Connor et al., 1996) and (Steger & Corbach, 1997) and is made with Adobe
Xd.

The AP-1 complex has an essential role in regulating viral oncogene expression (de
Marco et al., 2012). Transcription factors function by binding to regulatory sequences
on DNA, thus modulating the gene transcription (Garces de Los Fayos Alonso et al.,
2018). The active form of AP-1 has primary leucine-zipper domains (bZIP), which are

4

essential for the dimerization of the AP-1 complex and the binding to the DNA. The
12-O-tetradecanoylphorbol-13-acetate (TPA), a tumor-promoting agent, activates AP1, enabling it to bind to the TPA response element (TRE), which is located in the HPV
genome, as well as in the Autographa californica multiple nucleopolyhedrovirus
(AcMNPV)(Landais et al., 2006) .The binding of AP-1 to the TRE can also be induced
by cytokines, different growth factors, and oncoproteins. The interaction of TPA and
AP-1 leads to increased cell survival, proliferation, differentiation, and transformation
(Garces de Los Fayos Alonso et al., 2018).

1.4 The Notch pathway
The Notch signaling cascade is an evolutionarily conserved signaling pathways
(Kwon et al., 2012). Notch is involved in many biological processes ranging from
regulating stem cells and development and maintaining homeostasis in the adult tissue.
Both abnormal upregulation and downregulation of Notch signaling activity can result
in developmental anomalies and cancer. Therefore, the precise regulation of Notch
activity is necessary for normal cell function (Kwon et al., 2012).
Notch signaling is activated through cell-cell contact where transmembrane ligands
bind to transmembrane receptors to activate the signaling cascade (Kwon et al., 2012).
In mammals, four variants of the transmembrane receptors belonging to the Notch
family have been identified (Notch 1–4). Five known Notch ligands exist: Jagged1
(JAG1) and Jagged2 (JAG2) belonging to the Delta/Serrate/Lag-2 (DSL) family, and
Delta1 (DLL1), Delta3 (DLL3), and Delta4 (DLL4) belonging to the delta-like family
(Kwon et al., 2012).
The canonical Notch signaling pathway is activated by a trans (between to cells) and
cis (same cell) interactions between Notch receptors and ligands (sending cell) (Kopan
& Ilagan, 2009) (Kwon et al., 2012). The ligand interaction with the Notch receptor's
extracellular domain (ECD) leads to a two-step proteolysis cleavage by
metalloprotease from the ADAM/TACE family and γ-secretase complex. This
releases the Notch ICD (NICD) into the cytoplasm. NICD translocate into the nucleus,
where it associates with DNA-binding proteins and co-activators to assemble the CSL
complex, which then activates downstream target genes (Kwon et al., 2012) (Figure
4.)
5

Figure 4. The canonical Notch pathway. The Metalloproteases ADAM cleaves the juxtamembrane
part of the Notch receptor, which allows for the trans-endocytosis of the Notch ECD. The γ-secretase
complex cleaves in the remaining Notch receptor's transmembrane domain, liberating the NICD into
the cytoplasm. The cleaved NICD can now migrate into the nucleus and transcribe the target genes.
Created with BioRender.com.

The Notch and AP-1 crosstalk in CC has been extensively studied, with contradictory
results. Talora et al. (2002) show that Notch1 inhibits the growth of HPV-positive cell
lines. They also show that HPV transcription of E6/E7 oncogenes is down-regulated
by NICD that suppresses AP-1 activity by increasing c-Fra protein expression and
decreasing c-Fos protein in Hela cells (Talora et al., 2002). Notch1 thus suppresses
the expression of E6/E7 oncogenes which has protective effects against HPV-induced
transformation. In later stages of carcinogenesis induced by HPV, the downregulation
of Notch1 signaling can play an essential role in carcinogenesis. The same group later
showed that the modulation of AP-1 by NICD is not a common mechanism in all cell
lines derived from CC (Talora et al., 2005).
Contrary, Henken et al. (2012) proposes that the effect of Notch on AP-1 modulation
is dosage-dependent and that moderate levels of Notch expression increase AP-1
6

activity, leading to an oncogenic effect in CC cells (Henken et al., 2012). They show
that elevated levels of Notch expression in CC cells change the composition of the
AP-1 complex components from c-Jun/cFos to the non-tumorigenic c-Jun/c-Fra
variant. In the early stages of transformation, the expression of Notch is increased, but
in an already transformed cancer cell line, the expression is decreased, which suggests
that the effect over AP-1 by Notch is dosage-and stage-dependent.

1.5 The Jagged1 protein (JAG1)
JAG1 is a member of the Delta/Serrate/Lag-2 (DSL) family of proteins known as
Notch ligands (Ascano et al., 2003). The JAG1 protein has a short intracellular domain
(ICD), a transmembrane domain, and a larger extracellular domain (ECD). The JECD
bears an N-terminal region, a very conserved DSL domain, EGF repeats, and an area
rich in cysteines (figure 5). For JAG1 to bind to the Notch receptor, the DSL domain
of JAG1 is needed, and the EGF repeats are increasing the affinity of the binding
(Grochowski et al., 2016).
JAG1 mutations have been linked with various forms of diseases, including cancer
(Grochowski et al., 2016). Tripathi et al. (2018) show that an altered expression of
JAG1 in CC cells deregulates the Notch pathway, which might have an essential role
in the infection of the cervical mucosa. This might increase proliferation, which in
turn may lead to accumulation of additional genetic damage (Tripathi et al., 2018). In
ISCC and ADC HPV-related pre-malignant lesions, there is an increase in the nuclear
and cytoplasmic expression of JAG1 associated (Tripathi et al., 2018).
How JAG1 is regulated in cervical carcinogenesis has been poorly studied. The
processing of JAG1 and possible repercussions on AP-1 in cervical cell lines has not
been determined. As stated before, different HPVs harbor variable numbers of binding
sites for AP-1 on their its LCRs; thus, the interplay between JAG1 and AP-1 could be
an essential way of differentially regulating the HPV transcriptional activity. Since
there are suggestions that JAG1 and its cleaved forms can have a synergistic interplay
with HPV, it is essential to explore the processing of JAG1 in CC and its role in AP1 activity.

7

The DSL ligands JAG1, DLL1, and DLL4, have PDZ (PSD-95/Dlg/Zo-1) binding
motifs at their cytoplasmic tails. The PDZ domain allows for interactions between
scaffold or adaptor proteins (D’Souza et al., 2010). The PDZ-domains have an
essential role in anchoring the ligand to the membrane. The PDZ-domain also
regulates signaling pathways, and promoting cell-cell adhesion (Ho-Jin Lee & Zheng,
2010). The PDZ-domain does not play a role in JAG1 Notch-mediated signaling, but
it has a great importance in transformation (Hye Jin Lee et al., 2015). The JICD
contains a nuclear localization signal (NLS), similar to the NICD fragment (Azimi &
Brown, 2019).

Figure 5. The JAG1 protein structure. A majority of the ECD of JAG1 consists of EGF repeats.
Within the DSL domain, the Notch-binding motif is found. On the ICD, the protein bears a PDZ binding
domain. The image is inspired by (Grochowski et al., 2016). Created with BioRender.com

JAG1 is cleaved by a regulated intramembrane proteolysis (RIP) process by the A
disintegrin and metalloprotease 17 (ADAM17) (LaVoie & Selkoe, 2003). This
cleavage yields a membrane-binding C-terminal fragment (CTF). Presenilin (PS)/γsecretase complexes then mediate cleavage of the CTF. This process releases the
JICD, which can enter the cell's nucleus. Nuclear translocation is driven by the nuclear
localization signal. Notch receptors and ligands are cleaved by the same mechanism
and may individually regulate each other's signaling (Grochowski et al., 2016). B3
cells treated with DAPT, which is an γ-secretase inhibitor, show an accumulation of
JAG1-CTF intermediate, proving that JAG1 is cleaved by γ-secretase in B3 cells
(Azimi & Brown, 2019). Hye Jin Lee et al. (2015) state that JICD can positively
modulate transcriptional activity through AP-1 and that NICD has been proven on the
8

contrary, to down-regulate the AP-1 induced transcriptional activity in Chinese
hamster ovary (CHO) cells, African green monkey kidney cells (COS7), and human
embryonic kidney (HEK) cells. (Hye Jin Lee et al., 2015) (LaVoie & Selkoe, 2003).

9

2. Objectives

The project aims to determine the modulation of the Human Papilloma Virus (HPV)
Long Control Region (LCR) by the JAG1 protein.
Specific objectives:
•

To determine the processing of JAG1 protein in Cervical Cancer-derived cell
lines

•

To explore the modulation of HPVs LCR by JAG1 and its cleaved form, JICD

•

To determine the interaction between JAG1 and JICD with AP-1 elements

10

3. Materials and methods
3.1 Cell culture
The cell lines used in the present project were: Hacat (spontaneously immortalized
human keratinocytes), C33A (squamous cervical carcinoma, HPV negative), Caski
(squamous cervical carcinoma, HPV16 integrated genome as well as related sequences
to HPV18), Siha (squamous cervical carcinoma, integrated HPV16 genome, 1 to 2
copies per cell), and Hela (cervical adenocarcinoma, HPV18 positive). Cells were
cultured in Dulbecco’s Modified Eagle’s Medium (DMEM) (Sigma) supplemented
with 10% FBS (Fetal Bovine Serum) (Sigma), 2 mM L-glutamine, and 100 U/ml
penicillin and 100 μg/ml streptomycin (Sigma). The cells were grown at 37 °C in a
humified atmosphere containing 5% CO2.
For some experiments, the cells were treated with a γ-secretase inhibitor, DAPT. This
was done to determine the mechanism behind the cleavage of JAG1 in CC cells. 10
μM of DAPT was added to the cells and incubated for 24 h at 37 °C in a humified
atmosphere containing 5% CO2.
3.2 Protein extraction and quantification
The cell must be lysed to be able to extract the proteins. To achieve this, either
mechanical stress or chemical reagents can be used. Mechanical stress can be done by
pipetting and tearing apart the cells physically. Chemical reagents, buffers with
different properties such as low pH or high salt concentration can also lyse the cells
(Islam et al., 2017).
In this project, radioimmunoprecipitation assay (RIPA) lysis buffer was used (table
1). RIPA buffer contains SDS, which denatures proteins and thus helps to break the
cells. Protease inhibitors were added to the buffer to help stabilize the proteins. 50100 ul of RIPA buffer with inhibitors was added to the cells, and then a plastic
scratcher was used to scrape the cells from the plate. The whole volume was passed
about ten times through a 30-gauge syringe. The samples were left on ice for 30 min
11

and then centrifuged for 10 min at 12 000 rpm to separate the lysate and cell debris.
The supernatant, which contains the proteins from the lysate, was moved to new
Eppendorf tubes.
Table 1. RIPA Lysis Buffer

Reagent

Final concentration

5 M NaCl

150 mM

0.5 M EDTA, PH 8,0

5 MM

1 M Tris, pH 8.0

50 mM

NP-40

1.0%

10% sodium deoxycholate

0.5%

10% SDS

0.1%

dH20
After the proteins have been extracted, the concentration of the total amount of
proteins can be quantified by colorimetric assays. This is done to make the samples
comparable. In this project, the Pierce BCA assay kit was used. BCA is soluble in
water and has a linear absorbance at 595 nm in increasing protein concentrations
(Thermo Fisher). A standard curve is needed to know the samples' protein
concentration, so a protein with a known concentration, bovine serum albumin (BSA),
was used to establish a standard curve.
The protein concentrations from the CC cell lysates were determined using the
Pierce™ BCA Protein Assay Kit (Thermo Fisher). Using microtiter plates, 25 μl of
each cell lysate was pipetted in duplicates, including the BSA. To each well, 200 μl
Bradford Working Solution was added. After incubation, the protein concentration
measurement was done at 595 nm in a Hidex Sense plate reader. To generate the
standard curve, the BSA absorbance values were used, and from which the protein
concentrations of the CC cell lysates could be determined.

12

3.3 SDS-PAGE
SDS-PAGE (sodium dodecyl sulfate-polyacrylamide gel electrophoresis) is a method
where an electrical field is used to separate proteins according to their size. The
mobility of the protein depends not only on the size but also on its charge and threedimensional structure. To successfully separate the proteins, they have to be denatured
(Gallagher, 2012).
A polyacrylamide gel is used in SDS-PAGE to separate the proteins in an electrical
field. The bigger proteins are more hindered from separating in the gel; meanwhile,
smaller proteins can move more freely, and this is why the proteins are separated by
size. Two gels of different characteristics are used to separate the complex mixture of
proteins. The upper gel is more porous, and the purpose of the upper gel is to
concentrate the proteins to an even concentration before the separation occurs. The
lower gel has a higher concentration of polyacrylamide and separates the proteins
according to size (Gallagher, 2012).
Before separating the proteins in an acrylamide gel, they have to be denatured into
their primary structure from their three-dimensional structure; this is due to the latter
possessing a native electrical charge, affecting the migration in a polyacrylamide gel.
Laemmli sample buffer is a denaturation buffer containing B2-mercaptoethanol, SDS,
bromophenol blue, and glycerol. B2-mercaptoethanol denatures the proteins by
cleaving intra- and inter-molecular disulfide bonds. SDS forces proteins to linearize
due to the SDS molecule's negative charge, which disturbs the tertiary structure of
proteins. Bromophenol blue functions as an indicator dye to help the samples' loading
process into the polyacrylamide gel. Glycerol helps make the samples denser and
prevents the leakage of samples into other wells. A known molecular weight marker
is added in a separate well to estimate the sizes of the proteins of interest. 50 μg of
proteins were loaded per sample, and the acrylamide gels' concentration varied from
8-10%. The gels were run for 1.5-2 hours at 100 voltages (V).

13

3.3.1 Western blot
After the separation in the polyacrylamide gel, the proteins are transferred to a
nitrocellulose membrane, which has a high affinity for proteins. A transfer machine
that can generate an electrical current is used for this. The polyacrylamide gel
containing the proteins is placed on the negative side of the nitrocellulose membrane,
and they are surrounded by thick filter paper and sponges (figure 6). The stack is
submerged in the transfer machine. The negatively loaded proteins migrate towards
the positive anode, where the nitrocellulose membrane is. The transfer is done in a
transfer buffer, which contains methanol which helps the proteins bind to the
membrane, and it also unbinds the SDS from the proteins. After this, the proteins on
the membrane can be screened for with immunoblotting. The transfer was run with
the settings 100 V for 1 hour. To determine the efficiency of the transfer, the
nitrocellulose membranes were submerged in Ponceaus S solution (Sigma-Aldrich).
The membranes were washed 3 times in MQ-water and PBS with 0.05% Tween 20
(PBS-T).

Figure 6. Western blotting. After the proteins have been separated by the SDS-Page method, they can
be transferred to a nitrocellulose membrane, which has a high affinity for proteins. The gel is placed on
top of a membrane, which allows the proteins to wander to the positive node due to the negative charge
of the stack's proteins, which enables the proteins to transfer to the membrane. Figure done with
PowerPoint.

14

3.3.2 Immunoblotting
Immunoblotting is a method used to detect proteins using substrate-specific antibodies
(Counts, 2010). The nitrocellulose membrane binds unspecific proteins, and to hinders
this binding, the membrane has to be blocked by incubating in a buffer containing
milk. The membranes were blocked with 3-5% milk in PBS-T solution for 1h at room
temperature by rocking movement. Once the blocking was done, the membranes were
washed in PBS-T to get rid of the excess blocking solution. Then the membranes were
incubated at +4 °C with a primary antibody that binds specifically to the target protein.
For protein detection, a secondary antibody is used, which specifically binds to the
primary antibody. The secondary antibody is conjugated with the enzyme horseradish
peroxidase (HRP). The next day to primary antibody incubation, the membranes were
washed 3-4 times with PBS-T, whereafter they were incubated for 1 h at room
temperature with the HRP-linked secondary antibody. Once more, the membranes
were washed with PBS-T and incubated in Chemiluminescent (ECL) Western Blot
Luminol Reagent, which contains luminol, that is oxidized by HRP. This reaction
emits light in low intensity. ECL amplifies the reaction, and light detection is more
sensitive. The iBright (Invitrogen) imaging system was used to detect the light signal.
In order to make samples comparable, a loading control was used. Antibodies against
proteins found richly in the cells can be used. One of the highly conserved, nonmuscle
cytoskeletal actins, β-actin, is often used to control loading, and any differences in the
β-actin levels might suggest uneven loading of proteins. Table 2 shows the antibodies
and concentrations used.

15

Table 2. Antibodies used for western blotting.
Antibody

Source

Concentration

Molecular

Weight

(kDa)
Jagged1 (28H8)

Cell Signaling

1:1000

180

Notch1 (D1E11)

Cell Signaling

1:1000

120, 300

Dll1 (C-20)

Santa Cruz

1:1000

70

Dll4 (#2589)

Cell Signaling

1:1000

75-80

c-Jun (60A8)

Cell Signaling

1:1000

43, 48

c-Fos

Cell Signaling

1:1000

62

Fra1

Cell Signaling

1:1000

40

β-actin #4967

Cell Signaling

1:1000

45

3.4. Cloning
Cloning is done to generate copies of a gene of interest which utterly will be translated
into a protein. The foreign DNA is inserted into a plasmid, an independent small
circular DNA carrier from bacteria. Plasmids contain antibiotic resistance genes for
bacterial selection, DNA sequences that act as the origin of replication (ORI), which
allows the plasmid to multiply within the cell, and a Multi cloning site (MCS) enriched
in restriction enzymes sequences for introduction of the foreign DNA (Brown, 2006).
The cloning plasmid or vector is treated with restriction enzymes that cleaves the
DNA where the foreign DNA will be inserted (Brown, 2006). The restriction enzymes
have to be chosen suitably to ensure the correct position cuts and ensure no cuts will
be made in the foreign DNA introduced. HindIII, which recognizes the AAGCTT
sequence, and XbaI, which recognizes the TCTAGA sequence, are examples of
restriction enzymes used to clone DNA. It is essential to know if the restriction
enzymes being used are cut in a sticky or blunt end fashion. Many restriction enzymes
just cut the double-stranded in the middle of the sequence it recognizes, resulting in a
blunt end, while others do not cut the DNA at the same spot on the two strands; making
the DNA staggered, which results in an overhang at each end, and these are called
sticky ends.

16

The final step of the cloning process is to ligand together the plasmid backbone DNA's
opened ends, with the gene of interest; this process is referred to as ligation, catalyzed
by the enzyme DNA ligase (figure 7) (Brown, 2006).

Figure 7. Insertion of a genetic sequence into a plasmid vector. If a gene is to be inserted in a plasmid
vector, the vector backbone needs to first be cleaved open so that the gene can be inserted. The gene
can be ligated into the backbone using suitable ligands, and the result is a recombinant DNA molecule.
Picture taken from (Brown, 2006).

3.4.1 PCR
PCR or Polymerase Chain Reaction is used to generate multiple copies of a specific
gene (Hoseini & Sauer, 2015). The PCR utilizes a DNA polymerase called Taq
polymerase, which is stable at high temperatures. The polymerase itself cannot
synthesize DNA without primers which are, short (usually around 20 nucleotides)
sequences of nucleotides, and act as the starting point for the DNA's synthetization.
The DNA sequence that is of interest should be compatible with the primer sequence
or flank the region. The primers bind to the DNA through complementary base pairing.
The reagents needed to do PCR are mixed in a tube (master mix) (table 4), which is
then put through heat- and cooling cycles that help the polymerase synthesize the
DNA. The steps of the PCR reactions are denaturation, annealing, and extension.
17

Denaturation, which is done at 96 °C, heats the samples, separating the DNA strands
from each other, making the DNA single-stranded. The annealing phase, which is
performed at a temperature depending on the specific primers, cools down the samples
so that the primers can bind to the complementary sequence of the single-stranded
template DNA. In the extension phase, the temperature is raised to 72 °C so that the
Taq polymerase can start to synthesize the DNA. These cycles are repeated many
times depending on various factors, such as the template DNA length.
The PCR reaction was done to amplify the insert DNA. In this case, a plasmid
containing the sequence for the human JAG1 gene was used as a template to generate
the inserts to be cloned. A Histidine tag was added to the N-terminal to each of the
inserts (His-JAG1 and His-JICD). The PCR master mixture was prepared on ice. The
compounds needed for the mixture were first melted in RT. The reagents were pipetted
together and put in small PCR tubes for the PCR cycle (Table 4).

Table 4. Reagents used for PCR master mix.
Volume = 20 μl

1 reaction

H20

13.6 μl

5x buffer

4 μl

10 mM dNTP's

0.4 μl

Forward primer

0.1 μl

Backward primer

0.1 μl

DNA

1 μl

DMSO

0.6 μl

Enzyme

0.2 μl

18

3.4.2 Plasmid and insert digestion
After the amplification of the DNA, the restriction enzymes XbaI and HindIII were
used to achieve double digestion of the pCDNA 3.1 (+) plasmid and the inserts to
generate sticky ends. The restriction enzymes were mixed in a sterile 1.5 ml Eppendorf
tube as follows (table 5):
Table 5. Digestion conditions for cloning
1 μl XbaI
1 μl HindIII
5 μl buffer 2.1
28 μl DNA
15 μl of H2O
The mixture was put on a heat block for 1.5 h at 37 °C. The enzyme inactivation was
done at 80 °C for 20 min.

3.4.3 Visualization of the DNA fragments
After the digestion, the fragments were run on a 0,7% agarose gel for 40-60 min. This
is a technique where DNA fragments move through a gel matrix with an electrical
current, which separates the DNA fragments depending on size. A ladder of a known
size is used to help determine the fragment size of interest. The DNA can be cut and
isolated from the agarose gel and purified to be used in further methods (Abraham et
al., 2017). To determine if the digestion of the backbone was complete, a linear band
at the correct size should be visible in the agarose gel.

3.4.4 Gel excision of DNA fragments
A sterile scalpel was used to excise the bands from the agarose gel. UV light was used
to visualize the DNA, which was stained with SYBR green. The DNA fragments were
cut out from the gel and put in sterile 1.5 ml Eppendorf tubes. To extract the DNA
fragments from the agarose gel, QlAquick gel extraction kit from QIAGEN was used.
19

The gel slice was weighed, and 3 volumes of Buffer QC to 1 volume gel were added.
The mix was incubated at 50 °C for 10 min. 1 gel volume of isopropanol was added.
A QlAquick spin column was used for centrifugation for 1min until all the samples
passed through into the Eppendorf tube. The flow-through was discarded, and 750 μl
of Buffer PE was used to wash the column by centrifugation for 1 min. The QlAquick
column was placed into a sterile Eppendorf tube, and the DNA was eluted with 30 μl
of buffer EB (10 mM Tris-Cl, pH 8,5). The concentration of the eluted DNA was
measured with Nanodrop spectrophotometer.

3.4.5. Ligation of the Plasmid and the DNA fragment
To ligate the DNA fragment into the plasmid, a mixture of different reagents and
buffers were used in different ratios to see which ligation/DNA ratio worked the best
for the fragment and plasmid annealing (table 6). The mixture was incubated at 16 °C
in a thermocycler O/N.
Table 6. DNA ligation condition for cloning.
Reagent

1/3 ratio

1/5 ratio

Empty control

T4 DNA ligase buffer

2 μl

2 μl

2 μl

3 μl

2.74 μl

pCDNA 3.1 (+) plasmid (18.2 2.74 μl
ng/ul)
Insert (JAG1 (3.1 ng/ul))

12.09 μl

16 μl

0 μl

H20

2.20 μl

0 μl

14.3 μl

T4 DNA ligase

1 μl

1 μl

1μl

3.4.6 Transformation
The mix of recombinant DNA molecules can then be introduced into living cells, such
as bacteria; after the cells have grown for a while, they can produce more clones. The
purpose of this is to amplify the amount of recombinant DNA. The recombinant DNA
plasmid is taken up by living bacteria, and then when the bacteria are multiplying, so
is the recombinant DNA; this process is referred to as transformation. After this, the
20

DNA is purified and can be used in other methods, such as transfection of mammalian
cells. In this project, cloning was used to generate different variants of JAG1 to further
transfect into the CC cells.
In an Eppendorf tube containing DH5α competent cells, 5 μl of DNA was added and
gently mixed by tapping. The mixture was then incubated for 30 min on ice, whereafter
they were heat-shocked for 1 min at 42 °C and then put on ice for 2 min. 500 μl of 50
μg/ml ampicillin was added into LB-medium and incubated for 30 min up to 1 h at 37
°C. With an L-shaped rod, 250 μl of cells were plated onto an ampicillin plate, and the
cell dishes were incubated O/N at 37 °C in an incubator. The next day, the plates were
analyzed for the presence of colonies. Ten colonies per plate were subjected to PCR
amplification with the above-mentioned conditions (section 3.4.1).

3.4.7 Plasmid DNA isolation (Maxiprep)
A method called maxiprep is used to purify and isolate plasmids from bacteria. The
method consists of three main steps: growing the bacteria culture, harvesting and
lysing the bacteria, and purifying the plasmid DNA inside the bacteria.
Plasmid DNA is often isolated from liquid bacteria cultures. The plasmid encoded in
the bacteria contains a sequence for antibiotic resistance, usually ampicillin or
kanamycin, which act as a selection marker. This allows the bacteria containing the
plasmid DNA sequence to multiply; meanwhile, the bacteria lacking the sequence will
die.
During the first day of maxiprep, the bacteria culture is started for growth. LB (LuriaBertani) medium is used for growing the bacteria, the cells are grown at 37 °C with
constant shaking for 12-16 h. The cells are pelleted through centrifugation at 6000 x
g for 10 min at 4 °C; after this, the supernatant is completely removed. The cells are
then resuspended in 12 ml Resuspension Buffer RES + RNase A by pipetting the cells
so that no clumps remain. After resuspending the cells, 12 ml Lysis buffer LYS is
added and mixed by inverting the flask and incubated at RT for 5 min. While the cells
are incubated, the NucleoBond® Xtra Column is set up according to protocol. The

21

column is equilibrated with Equilibration Buffer EQU by applying 25 ml of the buffer
to the rim of the filter. The column should be allowed to empty before proceeding.
After this, 12 ml Neutralization Buffer NEU is added to the cell suspension and mixed
by inverting the flask until the suspension is colorless. The suspension is then added
to the column filter. After the cell suspension has dripped for a while, the
NucleoBond® Xtra Column Filter and Nu- cleoBond® Xtra column were washed with
15 ml Equilibration Buffer EQU; after this, the filter is removed.
The column is then washed with a washing buffer WASH. The plasmid DNA is eluted
with Elution Buffer ELU, and the elute is collected in a 15 ml centrifuge tube. To
precipitate the eluted plasmid DNA, 10.5 ml RT isopropanol is added and centrifuged
at 15 000 x g for 30 min at 4 °C. The supernatant is then discarded. 4 ml of 70% RT
ethanol is added to the pellet and centrifuged at 15 000 x g for 5 min at RT. The ethanol
is carefully removed by pipetting, and the pellet is dried at RT.
The dried plasmid pellet is dissolved in an appropriate volume of buffer TE or sterile
H2O, and the yield is determined by UV spectrometry.

3.5. Cell transfection
Transfection is a method used to introduce nucleic acids (DNA) into eukaryotic cells
by nonviral methods, using various chemical or physical methods instead. The main
goal in transfection is to express recombinant proteins or to inhibit or enhance gene
expression. Thus, transfection is a powerful method to analyze the function and
regulation of genes or proteins. In this work, FuGENE® HD Transfection Reagent
(Promega) was used to introduce the foreign DNA into the cells.
Plasmid vectors or mRNA can be used to introduce foreign genetic material into
cultured cells. The expression of the wanted protein can be achieved due to
recombinant proteins, and, thus, the expressed protein can be produced with proper
folding and posttranslational modifications (PTM) needed. If a detectable marker is
added to the protein of interest, it allows the study of promoters, enhancers, or proteinprotein interactions.
22

FuGENE® HD Transfection Reagent was used to transfect the CC cells. The right
amount of DNA to be added was calculated according to the concentration of plasmids
and the recommended amounts provided in the FuGENE protocol. One day before
transfection, the cells were counted and plated according to the protocol so that the
cells were approximately 80% confluent. Transfections were performed in 12-well
plates with a total of 1 μg of DNA per well. The ratio of plasmids to be transfected
were determined as followed: 100 ng of reporter, 100 ng of transfection control and
variable amounts of JAG1 and JICD, and pCDNA to complete the total 1μg of DNA.
The DNA to be transfected, FuGENE® HD Transfection Reagent, and OPTIMEM
media were mixed and incubated at RT for 10 min. After this, the mix was pipetted to
the plate and gently mixed. The plate was incubated for 24-72 h in a 37 °C cell
incubator.

3.6. Renilla Luciferase Reporter Assay
The Renilla luciferase reporter assay is used to study gene expression at the level of
transcription. It is used to determine whether a protein can activate or repress the
expression of a target gene. The assay can be used to measure the expression of a
cloned gene, which is fused with the DNA coding sequence for Renilla luciferase. If
the protein is upregulating the target gene, the cells will express luciferase. If the
protein downregulates the target gene expression, the cells will express less luciferase.
Luciferase is a monomeric protein derived from the firefly Photinus Pyralis. This
protein is used as a reporter vector for gene expression. The catalytic reaction is driven
by oxygen, luciferin, and energy converted into oxyluciferin and light energy (figure
8). The light energy can be measured with a luminometer, which gives a quantitative
reading. The light energy which is emitted is proportional to the amount of gene
expression of the target gene. To normalize the transfection values, a control reporter
will be used.

Figure 8. The reaction of the luciferase reporter assay.

23

24 hours post-transfection, the cells were carefully washed with RT PBS. 75 μl of
Dual-Glo® Luciferase Assay Reagent was added to each well, and the plate was
incubated at RT for 30 min on a shaker, after which the firefly luminescence was
measured with the Hidex luminometer. After the measurement, 75 μl of the DualGlo® Stop & Glo® Reagent was added to the plate, and the plate was again incubated
for 10 min in RT on a shaker. After the incubation, Renilla luminescence was
measured with the same Hidex luminometer. After the measurements, results were
normalized by Luciferase: Renilla ratio.

3.7. Proliferation assays
Proliferation assays are used to measure the proliferation of cells, cell viability, and
sometimes cytotoxicity. After various treatments, these assays can be used to control
the condition of the cells. Depending on the wanted results, different assay methods
can be used.

3.7.1 Colorimetric cell viability (WST-8) assay
In this assay, tetrazolium salt WST-8 is used on cells to determine the number of viable
cells in a cell culture (Chamchoy et al., 2019). Cellular dehydrogenases reduce WST8 to an orange dye called formazan, which is soluble in the cell medium. The amount
of formazan produced is proportional to the number of living cells in culture. The
optical density (O.D) is measured at 450 nm.
The day before the viability assay was done, an appropriate number of cells were
plated in a cell culture plate and transfected with 1 μg of pCDNA3.1 (+), JAG1, or
JICD. 10 μl of CCKV-1 solution was added to each well, and the plate was incubated
at 37 °C for 1 h. The O.D was read at 450 nm to determine the cell viability after the
transfection.

24

3.8. Co-Immunoprecipitation
Co-Immunoprecipitation (co-IP) is a technique used to pull down, or precipitate
proteins with an antibody that recognizes the protein of interest. In a sample of cell
suspension, all the proteins expressed in the system are present, and through IP, it is
possible to isolate and concentrate one protein from the suspension. Using an antibody
of interest to treat the cell lysate, the antibody-protein complex can be separated using
an antigen-binding structure, such as sepharose A beads bound to the antibody. The
interaction between the antibody and the protein complex can then be detected by WB.
The beads are coated with protein A which binds with high affinity to antibodies,
allowing for the interaction. Co-IP is done to see whether a protein-protein interaction
is present. The first antibody is used to precipitate, and a second antibody is used for
immunoblotting. If an interaction exists, both antibodies will show corresponding
bands in the blot.
Fully confluent 10 cm dishes were lysed using RIPA buffer with protease inhibitors,
and from this, the input control was collected. First, the sepharose A coated beads
were washed in 1 ml of PBS + 0.1% BSA for 30 min on rotation. The beads were then
centrifuged at 350 x g for 2 min, and the supernatant was discarded. The beads were
resuspended in 400 μl RIPA lysis buffer. 5 μl of the primary antibody against the Cterminal tail of JAG1 protein or c-Jun antibody and the control IgG were added to 50
μl of washed beads and incubated at RT for 1 h. 400 μl of protein was added to the
beads and incubated O/N at 4 °C in rotation. The next day the beads were centrifuged,
and the supernatant discarded; the mixture was washed 3 times with PBS and then
centrifuged again. Proteins were resolved by electrophoresis and immunoblotting for
detection.

25

4. Results
The participation of the JAG1 protein in cervical carcinogenesis has been poorly
studied (Tripathi et al., 2018). The processing of JAG1 and liberation of the ICD and
the activity of this has not been determined in CC. Thus, the possible regulation over
AP-1 and consequently over the HPV's LCR by JAG1 need to be addressed.

4.1 JAG1 is processed in CC cell lines

Figure 9. Western blot analysis showing endogenous levels of JAG1 protein in cell lysates from
CC cells. A. Endogenous levels of JAG1 protein in CC cell lines. The expression of JAG1 (180 kDa)
and its processed forms CTF (25 kDa) and JICD ( ̴ 20 kDa) can be seen. β-actin was used as a loading

26

control B. Densitometry analysis showing JAG1, CTF, and JICD protein expression. Data represent the
mean of three independent experiments.

In order to determine if JAG1 is processed in CC cell lines, we evaluated the
expression of JAG1, CTF and JICD proteins by WB. Endogenous levels of proteins
were evaluated with the 28H8 antibody raised against the C-terminal tail of JAG1. The
results in figure 9 show that JAG1 is processed in CC cells generating a C-terminal
Fragment (CTF) and an intracellular domain (JICD). The upper band corresponds to
the full length (FL) JAG1 (180 kDa) and the lower bands to the CTF (25 kDa) and
JICD (̴ 20 kDa), respectively. The cell lines Hacat, Caski, and Hela show higher
protein expression of the FL JAG1 and the processed forms CTF and JICD.

4.2 JAG1 is cleaved by γ-secretase in CC cells
It has been previously shown that JAG1 is processed by the metalloprotease ADAM17
and γ-secretase in several cell lines (Liebler et al., 2012). Here we determine whether
JAG1 is processed in CC cells by the γ-secretase complex (figure 10). CC cells were
treated with 10 μM of the γ-secretase inhibitor DAPT for 24 hours. The DAPT treated
cells show the loss of the JICD due to the inhibition of γ-secretase cleavage. These
results are in accordance with previous reports that showed that CTF is the substrate
of γ-secretase and JICD the product of that cleavage (Liebler et al., 2012).

27

A

B

Figure 10. JAG1 expression in CC cells following DAPT treatment. The cells were treated with N[N-(3,5-Difluorophenacetyl)-L-alanyl]-S-phenylglycine t-butyl ester (DAPT), which is a γ-secretase
inhibitor. A. Untreated cells. B. Cells treated with DAPT (10 μM). Inhibition with DAPT prevented the
release of the JICD.

4.3 Cloning of the intracellular domain of JAG1
In order to be able to overexpress JICD in CC cells, primers recognizing the JICD
region were used to amplify the JICD sequence from a previously available JAG1
plasmid (pCDNA3.1 (+) JAG1). The His-tag sequence (CAT CAT CAT CAC CAC
CAT) was added to the 5’ end of each primer. After PCR amplification, the insert and
the backbone were double digested with HindIII and XbaI restriction enzymes. The
products were cleaned and ligated with T4 ligase. Competent DH5α bacteria were
transformed with the pCDNA3.1His-JAG1 and pCDNA3.1His-JICD plasmids. The
colony PCR is presented in figure 11. Sequencing confirmed the presence of JAG and
JICD.

28

Figure 11. Colony PCR for screening positive colonies of DH5α with cloned JAG1 and JICD
plasmid. Four positive colonies expressing the His-JAG1 and His-JICD. In lane 1-2 are bacteria
colonies which successfully express JAG1 and in lane 3- 4 there are bacteria colonies expressing JICD.

C33A cells were transfected with the plasmids encoding for JAG1 and JICD.
Following overexpression, WB analyses were done to detect the proteins (figure 12).
In the first lane, there is a band corresponding to the expected size of FL JAG1 (180
kDa), and in the second lane, there is a band corresponding to the expected size of
JICD (̴ 20 kDa).

29

Figure 12. Western blot analysis on C33A cells transfected with JAG1 and JICD encoding
plasmids. Cells were transfected with 3 μg of plasmid encoding for JAG1 and JICD and blotted with
the 28H8 antibody. In the first lane, there is a corresponding band to the FL JAG1 (180 kDa), and in
the second lane, there is a band corresponding to the expected size of JICD (20 kDa).

4.4 JAG1 and JICD modulate the activity of the HPV 16 and HPV18 LCR
Transcriptional regulation of HPV is under the control of the LCR (Ribeiro et al.,
2018). Here we analyzed the modulation of HPV16 and HPV18 LCRs by JAG1 and
JICD. LCR luciferase reporter which reports the transcriptional activity of gene
activity, and plasmids encoding JAG1 or JICD were transfected into Hacat, C33A,
Caski, Siha, and Hela cells. An empty pcDNA 3.1 (+) plasmid was transfected as a

30

control. Luciferase results were normalized against the transfection control plasmid
(Renilla). Results are present in Figure 13.

31

32

Figure 13. Renilla Luciferase reporter assay shows the promoter activities of HPV16 and HPV18
under JAG1 and JICD overexpression. Cells were transfected with 100 ng of HPV16 or HPV18 LCR
reporter plasmids, 800 ng of JAG1/JICD plasmid, 100 ng of Renilla plasmid, and for negative controls,

33

800 ng of empty vector pcDNA3.1 (+). 24 h after transfection, the cells were lysed, and luminescence
activity was measured. ANOVA analysis was done to determine statistical significance. Data represent
the mean of three independent experiments, each performed in triplicate.

The HPV negative cell lines Hacat and C33A have no significant modulation of
HPV16 LCR under JAG1 or JICD overexpression. However, there is a decrease in
HPV18 LCR activity in Hacat cells, although not statistically significant. On the
contrary, the C33A cells show an increase in HPV18 LCR activity when JAG1 is
overexpressed.
In Caski cells, which are HPV16 positive, JAG1 overexpression induces a significant
increase of its autologous LCR (HPV16) activity. Unexpectedly, JICD overexpression
significantly decreases the activity of the autologous LCR even below the control
conditions. The HPV18 LCR was not affected by JAG1. However, JICD significantly
decreases the activity of HPV18 LCR also below control conditions. In the case of
Siha cells (HPV16 positive), the expression of JAG1 or JICD did not affect the
autologous activity of the LCR. The LCR from HPV18 was induced only by JAG1.
Finally, in the cell line Hela, which is positive to the HPV18 genome, the activity of
the non-related LCR from HPV16, was decreased by JAG1, although not significantly.
Of note, the HPV18 LCR is in all cases more active compared to the HPV16 LCR in
all the cell lines studied (appendix, S1). After these results, we decided to continue
with the positive HPV cell lines and address the modulation of their autologous LCRs.

4.5 The modulation of the LCR by JAG1 and JICD is dose-dependent
The dose-dependent effect of JAG1 and JICD expression over the LCR activity was
evaluated in Caski, Siha, and Hela cells. To determine if dosage differences would
affect the cells, we studied the effect of different concentrations of JAG1 and JICD.
For the low concentration we used (100 ng) (figure 14) of JAG1 and JICD plasmid.
By completing with empty vector plasmid, we ensured that the total amount of DNA
was kept at 1000 ng (Figure 14). In the high concentration experiments, we used 800
ng of JAG1 and JICD (figure 13). The results from this experiment are compared to

34

the results obtained from the previous experiment (figure 13), as well as to the changes
compared to the control conditions in this experiment.

35

Figure 14. The effect of JAG1 and JICD on the LCRs is dose-dependent in CC cells. The low
expression of JAG1 and JICD provokes a different response of the autologous LCRs compared to
experiments done with high concentration (figure 13). Data represent the mean of three independent
experiments, each performed in triplicate.

In Caski cells, the JAG1 modulation of LCR activity is affected by the concentration
of JAG1, a low expression of JICD provokes a significant decrease in HPV16 LCR
when compared to the high concentration. In Siha cells, the lower concentration of
JICD plasmid decreases the activity of LCR16; meanwhile, in HeLa cells, both lower
concentration of JAG1 and JICD overexpression increases the activity of HPV18 LCR
compared to a higher concentration of JAG1 and JICD, although not significantly.
Thus, the activity of the LCRs in the CC cells regarding a response to JAG1 and JICD
is dose-dependent.

4.6 The modulation of the HPV LCR in Caski cells is dependent on AP-1
activity
As mentioned before, JAG1 protein can modulate the activity of the transcriptional
complex AP-1 (LaVoie & Selkoe, 2003). Also, the HPV16 and HPV18 LCRs harbor
36

AP-1 responsive elements (O’Connor et al., 1996) (Steger & Corbach, 1997). Thus,
we aimed to determine if the observed effects of JAG1 and JICD modulation over
HPV16 and HPV18 LCRs is dependent on AP-1. Phorbol esters (TPA) regulates AP1, enabling it to bind to the TPA response element (TRE). 100 ng/ml of TPA was
added to cells overexpressing JAG1, JICD, or a control plasmid empty vector.
Figure 15 shows that in Caski, the HPV16 LCR activity is not affected in the control
conditions. As previously observed, JAG1 overexpression induces HPV16 LCR
activity which TPA significantly decreases. In the case of JICD, the downmodulation
of LCR activity is marginally restored by TPA. In Siha cells, the treatment with TPA,
shows no significant changes. On the contrary, Hela cells treated with TPA show
decreased HPV18 LCR activity compared to the non-treated cells, although not
significantly.
The results presented here suggest that in Caski cells the modulation of HPV16 LCR,
since we can only see a significant modulation by JAG1 which is dependent on AP-1
complex.

37

38

Figure 15. The modulation of HPV 16 LCR in Caski cells is dependent on AP-1 activity. One day
prior to the TPA treatment, the cells were transfected with their autologous LCRs, JAG/JICD, and
pcDNA3.1 (+). 100 ng/ml TPA was added 24 h after transfection and incubated for another 12 h, and
then Luciferase activity was measured. Data represent the mean of three independent experiments done
in triplicate.

4.7 CC cells express different protein levels of the AP-1 transcription
factor components
It is known that AP-1 is a heterodimer that consists of either c-Jun/c-Fos or c-Jun/cFra proteins. Depending on the composition, the transcription will be differently
modulated (Henken et al., 2012).
Western blotting was performed to detect the endogenous levels of AP-1 complex
proteins in the CC cells (figure 16, 17, and 18). Antibodies against c-Jun, c-Fos, and
c-Fra were used. The results are representative of three independent experiments. In
figure 16, it can be observed that there are high levels of c-Jun protein in Hacat, C33A,
and Caski cells. Figure 17 shows that the expression of c-Fos is higher in C33A, Siha,
and Hela cells than in Hacat and Caski cells. As seen in figure 18, Hacat expresses
high levels of c-Fra protein. The other four cell lines have an even level of expression.

Figure 16. C-Jun endogenous expression in CC cells. A. Western blot image of c-Jun expression in
CC cells B. Densitometry analysis of the levels of c-Jun. β-actin was used as the loading control.
Densitometry was done using ImageJ software. Data represent the mean of three independent
experiments.

39

Figure 17. c-Fos endogenous expression in CC cells. Western blot image of c-Fos expression in CC
cells B. Densitometry analysis of the levels of c-Fos. β-actin was used as a loading control.
Densitometry was done using ImageJ software. Data represent the mean of three independent
experiments

Figure 18. c-Fra endogenous expression in CC cells. Western blot image of c-Fra expression in CC
cells B. Densitometry analysis of the levels of c-Fra. β-actin was used as a loading control.
Densitometry was done using ImageJ software. Data represent the mean of three independent
experiments

4.8 JAG1 binds to c-Jun
To determine if a possible interaction between JAG1 and c-Jun exists in CC cells, coimmunoprecipitation was performed. Endogenous protein was immunoprecipitated
40

with JAG1 or the negative control IgG antibody. Western blots were done to analyze
the immunoprecipitations using a c-Jun antibody to see if an interaction exists.
Reciprocal precipitation was also done where c-Jun was pulled down using an
antibody against the protein, and then western blotting was performed with an
antibody raised against JAG1.
Figure 19 shows the Co-IP results of the CC cells using JAG1 antibody and
immunoblotted against c-Jun. Of the five cell lines used, all input samples show a band
at the corresponding size for c-Jun (43, 48 kDa). Meanwhile, in the precipitated
samples, there can be seen a weak band corresponding to c-Jun in Caski cell extract.
To confirm a successful immunoprecipitation of JAG1, the same membrane blotted
against JAG1 protein (figure 20). In the blot, we can see weak bands in the input
samples in Hacat, C33A, and Hela and a stronger band in Caski, which corresponds
to the FL size of JAG1 (180 kDa). In the immunoprecipitated samples, there can also
be seen weak bands in Hacat, C33A, and Hela and, again, a stronger band in Caski
cells of the FL JAG1 protein.

Figure 19. Immunoprecipitation showing JAG1 binding to c-Jun in CC cells. On the left is the
input samples showing a band at the corresponding size of c-Jun (43, 48 kDa), and on the right are the
pulled-down samples and the IgG control.

41

Figure 20. JAG1 Immunoprecipitation. To confirm a successful immunoprecipitation of JAG1, the
previous membrane was blotted against JAG1 to reveal if the pull down of the protein was done.

4.9.1 JAG1 binds to c-Jun in an overexpressed system
To further address the binding between c-Jun and JAG1, immunoprecipitation was
done in an overexpressed system with C33A cells (figure 21). The exact same protocol
for immunoprecipitation was used in this system as in the wild-type system. It is worth
noting that wild-type C33A cells have a lower JAG1 protein level than the other four
CC cell lines (figure 9), and this was the reason we chose this cell line. Both the C33A
samples overexpressed with JAG1 and JICD show a band at the corresponding size
for c-Jun (43, 48 kDa). The C33A samples overexpressing JICD have a bit stronger
signal than FL JAG1. In the immunoprecipitated sample, there are bands at ca. 40 kDa,
corresponding to the c-Jun protein.

42

Figure 21. Immunoprecipitation of JAG1 and blotting with c-Jun in an overexpressed system.
C33A cells were transfected with JAG1 and JICD, and co-immunoprecipitation was performed. On
lanes 1 and 2 inputs, lanes 3 and 4 IP.

The reciprocal immunoprecipitation in the overexpressed system was also done. c-Jun
was pulled down and then immunoblotted against JAG1 protein (figure 22). The same
exact loading was done as in the previous figure. In the input on the left, there is not a
signal detected at the 180 kDa where JAG1 is expected, but in the JICD
overexpressing sample, there is a strong signal at the JICD corresponding size (20
kDa). In the C33A JAG1 overexpressed cells, there cannot be seen a band at 180 kDa;
meanwhile, in the C33A JICD overexpressing cells, there is again a signal at the
corresponding size for JICD.

43

Figure 22. The reciprocal of overexpressed C33A immunoprecipitation for c-Jun. The C33A cells
were first transfected with plasmids encoding for JAG1 and JICD genes, and then immunoprecipitation
on them was performed. C-Jun antibody was used to pull down c-Jun antibody and immunoblotted with
JAG1 antibody. To be able to detect the antibody, a long exposure time had to be used, this also affects
the exposure of the IgG and thus making it overexposed.

4.9 JICD decrease the proliferation of Caski and Hela cells
To determine if the proliferation of the CC cells was affected due to the overexpression
of JAG1 and JICD, cell proliferation was measured by WST 8 assay. As shown in
figure 23, Caski and Hela cells transfected with JICD have a decreased proliferation,
although not significant. This could indicate that JICD overexpression in these cells
can reduce cell division. Siha cells showed no effect on their proliferation after JAG
or JICD overexpression.

44

45

Figure 23. JICD decreases the proliferation of Caski and Hela cells. WST 8 cell proliferation assay
shows decreasing proliferation in Caski and Hela cells transfected with JICD. 10 μl of CCKV-1 solution
was added to cells and incubated for 1 h at 37 °C. Absorbance was read at 450 nm. Data represent the
mean of three independent experiments done in triplicate.

46

5. Discussion
CC is the fourth most common cancer type in women worldwide (Abryn et al., 2020).
Globally in 2018, there were 570 000 cases of CC and 310 000 deaths. CC occurs due
to a persistent infection with HPV, which is a sexually transmitted pathogen. Infection
with HPV alone is not enough for CC development, and other cofactors are needed.
HPV is related to many cancer types, such as cervical, anal, penile, and vaginal. The
HPVs are divided into hr, and lr types depending on their abilities to provoke cancer
(Ribeiro et a., 2018). Hr-variants, such as HPV16 and 18, are accountable for ca. 55%
of Invasive squamous cell carcinomas (ISCC).
There are over 100 types of HPVs, and ca. 30 are associated with genital tract lesions
(Ottinger et al., 2009). The HPV genome is divided into three regions: The long
control region (LCR), the early (E), and the late expression (L) regions (Chakravorty
& Sugden, 2018). HPV carcinogenesis is mainly due to the E6 and E7 oncoproteins;
when episomal HPV is integrated, the oncoproteins E6 and E7 increases and blocks
the tumor suppressors p53 and pRB, which leads to cellular transformation (OrganistaNava et al., 2019). Thus, regulation of the expression of viral oncogenes is essential
for tumor initiation.
JAG1 is a member of the Delta/Serrate/Lag-2 (DSL) family of proteins known as
Notch ligands (Ascano et al., 2003). The participation of JAG1 in cervical
carcinogenesis has been poorly studied. The processing of JAG1 and possible
repercussions on AP-1 in cervical cell lines has not been determined. Different HPVs
harbor variable numbers of binding sites for AP-1 on their LCRs (figure 3) (O’Connor
et al., 1996) (Steger & Corbach, 1997); thus, the interplay between JAG1 and AP-1
could be an essential way of HPV transcriptional regulation. Since there are
suggestions that JAG1 and its cleaved forms can have a synergistic interplay with HPV
(Tripathi et al., 2018), it is essential to explore the processing of JAG1 in CC and its
role in AP-1 activity.
Talora et al. (2002) show that in Hela cells, Notch1 inhibits cell proliferation by
downmodulating the E6 and E7 oncogenes (Talora et al., 2002). The group also

47

showed that the modulation of AP-1 by NICD is not a common mechanism in all the
CC cell lines (Talora et al., 2005).
Contrary, Henken et al. (2012) propose that the effect of Notch over AP-1 modulation
is dosage-dependent and that moderate levels of Notch expression increase AP-1
activity, leading to an oncogenic effect in CC cells (Henken et al., 2012). They show
that elevated levels of Notch expression in CC cells change the composition of the
AP-1 components from c-Jun/cFos to the non-tumorigenic c-Jun/c-Fra variant.
Since the participation of JAG1 in cervical carcinogenesis had been poorly studied, in
this project, we used cervical cancer-derived cell lines to determine the processing of
JAG1 protein and the modulation of the HPVs’ LCR by JAG1 and JICD proteins.
Additionally, we assessed the interaction between JAG1 and JICD with AP-1
elements.
The results presented in this work show that JAG1 protein is cleaved in CC cell lines.
We also present evidence that the activity of HPV16 and HPV18 LCR is modulated
by the overexpression of JAG1 or JICD, in a cell type-specific manner. We explored
the possibility that HPV LCR modulation by JAG1 or JICD could be through the AP1 transcription complex. We found that in the Caski cell line (HPV 16), the
transcriptional modulation of the LCR is occurring through AP-1. We further
determined the interaction between JAG1 and the c-Jun protein, an essential element
of the AP-1 complex.

5.1 JAG1 is processed in CC cells
LaVoie & Selkoe (2003) demonstrated that the Notch ligands could be proteolytically
processed in a way that resembles the activation of the Notch receptor. The ICD of the
ligands has been found in the nucleus of HEK, COS7, and CHO cells (LaVoie &
Selkoe, 2003). The presence of JICD has also been observed to regulate cardiac
homeostasis (Forghany et al., 2018), but the processing of JAG1 in CC has not been
determined. We performed WB analysis of endogenous protein from the CC cell lines
Hacat, C33A, Caski, Siha, and Hela. We blotted with JAG1 antibody raised against
the C-terminal tail of JAG1, which recognizes all the cytoplasmic forms of the protein.

48

In figure 9A, we show the expression of JAG1 (180 kDa). There are two bands
corresponding to CTF and JICD around 25 and 20 kDa. As reported by LaVoie et al.
(2003) the CTF corresponds to the JAG1 protein lacking the ECD because of the
cleavage mediated by metalloproteases ADAM17 (LaVoie & Selkoe, 2003). The CTF
is the substrate for γ-secretase cleavage (Liebler et al., 2012). Of note, our results
regarding the expression of FL JAG1 in CC cell lines is in accordance with previous
reports (Veeraraghavalu et al., 2004), which mentions that JAG1 is highly expressed
in Caski cells. Also, the presence of CTF and JICD is higher in this cell line compared
to the other CC cell lines.
Previous work done on the expression of JAG1 in CC patient samples (Tripathi et al.,
2018), shows that both cytoplasmic and nuclear JAG1 expressions decrease in cancer
patients compared to pre-cancer patients. Our results suggest the contrary since we see
high levels of JAG1 protein in Hacat cells, which are non-transformed keratinocytes,
and lower expression of JAG1 in the other CC cell lines (figure 9). In addition, we did
not detect differences in the JAG1 expression considering the histological origin of
cells, since the squamous derived cell lines (Caski and Siha) had different expression
patterns between them. Hela cells, which is the only adenocarcinoma cell line
included, also has high expression of JAG1 and its cleaved forms, the same as Caski
and the non-tumorigenic Hacat cell line.
According to The Human Protein Atlas the expression of JAG1 is considered medium
in cervix and uterine tissues (Human Protein Atlas, JAG1). In previous work Pelullo
et al. (2014) show that JAG1 is undergoing constitutive cleavage through a lipid raftassociated constitutive processing, which allows the JICD to translocate to the nucleus
and increase Notch transcriptional activity. This has been shown to have an autocrine
effect through Notch which increases the transcriptional activity of JAG1 (Pelullo et
al., 2014). They also show that the released JECD has a positive effect on the
activation of Notch receptors during cell-cell contact. This signaling pathway
functions as an auto-sustaining loop between Notch 3 and JAG1 in T lymphoma cells.
It would be interesting to determine the expression of JICD and CTF in non-confluent
cell cultures to see if the cleavage is dependent on cell-cell contact, and if there would
be differences to confluent cell cultures. In these experiments we used cells that were
80-90% confluent.
49

The FL JAG1 protein can be seen expressed in all the cell lines, but Hacat, Caski, and
Hela express more of the protein. The CTF is also expressed in Hacat and Caski. JICD
is expressed in Hacat, Caski, and Hela cells. In the densitometry analysis of FL JAG1,
the levels of protein expressions are varying. In the densitometry analysis for CTF, the
levels are also varying but correspond to the JAG1 levels. It is notable that the levels
of JICD in Hela cells seem to be higher than of the CTF.
In conclusion, we show that JAG1 is processed in Hacat, Caski and Hela cells. It is
possible that when increasing the amount of protein in the blots, the results would
show processing of JAG1 in the other cell lines as well.

5.2 Processing of JAG1 in CC cells by γ-secretase
In many cell lines the processing of Notch and JAG1 by ADAM proteases and γsecretase has been observed. In Liebler et al. (2012) they demonstrate that JAG1 is
cleaved by γ-secretase in endothelial cells (Liebler et al., 2012). Since we observed
that JAG1 is expressed and processed in CC cells (figure 9), we wanted to see if the
same regulated intramembrane proteolysis (RIP) mechanism is responsible for the
processing of JAG1 in CC cells as well.
To find out if JAG1 is cleaved by γ-secretase in CC cells, the cells were treated with
DAPT, which is a γ-secretase inhibitor. The samples were immunoblotted with an
antibody raised against the C-terminal tail of JAG1, thus recognizing all cytoplasmic
forms of JAG1. In figure 10A we can see represented cells without DAPT treatment,
and B, represents cells treated with DAPT. CTF is around 25 kDa. Meanwhile, JICD
is 20 kDa; the difference in size is not remarkable but enough to be able to separate
from each other.
After DAPT treatment in Hacat and Caski cells, the formation of JICD is lost after γsecretase inhibition. In summary, these results indicate that in CC cell lines, the
processing of the JAG1 ligand requires γ-secretase activity, and that the processing
occurs through the same mechanism as Notch cleavage. This also means that we need

50

to take into consideration when inhibiting Notch with DAPT, that we could also be
inhibiting ligand processing. Indeed, others have shown that not only JAG1 is cleaved
by γ-secretase, but also JAG2 and DLL1 (Liebler et al., 2012) (Ikeuchi & Sisodia,
2003) as well as the Notch receptor. Thus, it is important to determine the impact of
ligand processing on Notch pathway activity. Other signaling pathways have also been
shown to be processed by γ-secretase, such as receptor tyrosine kinases (RTKs) which
are involved in the regulating of cell cycle, survival and differentiation(Merilahti et
al., 2017).
It has also been shown that there is a possibility that the processing of the ligands is
negatively regulating the Notch pathway since the constitutive cleavage of the ligands
regulates Notch (Pelullo et al., 2014). For each JICD molecule, there also has to be a
corresponding JECD molecule. It is possible that JECD could be inducing or inhibiting
Notch. In this regard, it would be interesting to determine the presence of JECD and
if it is able to activate Notch. This could be done by comparing cells transfected with
a plasmid encoding for JECD and determining the transcriptional activity of Notch
through luciferase assay or western blot analysis comparing to a control sample.

5.3 Cloning of the intracellular domain of JAG1
To be able to express the JICD protein, which is around 370 base pairs, we first had
to clone it into our pcDNA3.1 (+) backbone. The JICD and JAG1 protein was tagged
with a HIS-domain at the N-terminal. We chose this approach since the C-terminal of
JICD harbors important protein-protein binding domains that could be blocked by a
tag in that terminal. Once cloning was successful, the construct was transformed into
DH5α competent cells. First, we tried transforming the construct in another competent
cell line, JM109, and the number of positive colonies was very low (less than 10%).
This might be due to the fact that this bacterial strain is high in endogenous nucleases
(New England Biolabs), and after changing the competent bacteria strain to DH5α, the
transformation rate considerably increased (figure 11).
When we transfected C33A cells with our constructs, which normally have only a little
expression of JAG1 (figure 9), we could see both the FL and JICD using the same

51

antibody that previously. Hence, we could prove that the cloning was successful
(figure 12), the sizes seen in the FL JAG1 transfected cells correspond to the 180 kDa
size of the protein, and the JICD transfected cells show a band at the 20 kDa size,
which is the expected size of JICD. Our construct of JICD spans from the residue
R1094 to V1218 (Lim et al., 2015)

5.4 JAG1 and JICD modulates the activity of LCR in HPV
It has been demonstrated that JAG1 can modulate AP-1 and the HPVs harbor on their
LCRs binding sites for this transcriptional factor (figure 3) (O’Connor et al., 1996)
(Steger & Corbach, 1997). To be able to determine if JAG1 and JICD are able to
modulate the activity of LCR in CC cells, we transfected our constructs into the CC
cell lines: Hacat (spontaneously immortalized human keratinocytes), C33A
(squamous cervical carcinoma, HPV negative), Caski (squamous cervical carcinoma,
HPV16 integrated genome as well as related sequences to HPV18), Siha (squamous
cervical carcinoma, integrated HPV16 genome, 1 to 2 copies per cell), and Hela
(cervical adenocarcinoma, HPV18 positive).
In figure 13, we can see the modulation of the different LCRs when overexpressing
either JAG1 or JICD. Of note, the basal activity of HPV18 LCR was higher in all the
cell lines studied (the RLU is presented in appendix, S1). Since the results are reported
in fold change, this effect is masked. This is in accordance with Ottinger et al. (2009)
that show a higher activity of HPV18 LCR compared to HPV16 LCR in the following
cell lines: C33A, Hela, Siha, NOK hT (HTERT-immortalized human normal oral
keratinocytes), and BJ hT (Human BJ fibroblast cells immortalized with hTERT)
(Ottinger et al., 2009). It is worth mentioning that we observed a decrease in the
activity of HPV18 LCR in Hacat cells when overexpressing JAG1 and JICD, a
behavior that we did not see in HPV16 LCR. Since Hacat cells are non-transformed
keratinocytes free of HPV infection, this result might indicate that in an early infection
state, the expression of JAG1 can be protective from transformation through HPV18.
This is important since HPV18 is related to worse clinical prognosis and to the
generation of adenocarcinomas rather than squamous carcinomas (Lizano et al., 1997)
When Lizano et al. (1997) analyzed a sample from small-cell cervical carcinomas,
which has the worst prognosis compared to other lesions in the cervix, they found that
52

there were HPV18-positive tumors in the cell samples. Thus, it is important to
determine the significance of JAG1 as a prognosis marker in CC. It has been shown
that JAG1 is a negative marker in pancreatic cancer (The Human Protein Atlas, JAG1).
In Hacat, which is HPV negative, the basal activity of HPV18 LCR is the highest of
all the conditions, and it seems that when overexpressing JAG1 and JICD, the activity
of the LCR is decreased. The opposite happens in HPV16 LCR with JICD, where the
expression is slightly increased.
In C33A cells, which are also HPV negative, the overexpression of JAG1 and JICD
seems to have no effect on the activity of HPV16 LCR. Meanwhile, when
overexpressing JAG1, an increase in the HPV18 LCR can be observed upon JAG1
overexpression.
In Caski cells, which have integrated HPV16 genome and related sequences to
HPV18, the HPV16 LCR activity is clearly increased when overexpressing JAG1.
Meanwhile, when JICD is overexpressed, the activity is significantly decreased. The
activity of HPV18 LCR is significantly increased when JAG1 is overexpressed and
significantly decreased when JICD is overexpressed. Interestingly in Siha cells, which
are HPV16 positive, the activity of HPV16 LCR is very low (appendix, S1) and is not
affected by the expression of JAG1 or JICD. On the contrary, when overexpressing
JAG1, the activity of HPV18 LCR is significantly promoted. In Hela cells, which is
the only HPV18 positive cell type in these experiments and an adenocarcinomaderived cell line, the overexpressing of JAG1 decreases the activity of HPV16 LCR,
and the changes in JICD are not significant. Although, the activity of its autologous
LCR (HPV18) is not affected by JAG1 or JICD.
The results suggest that the modulation of HPV LCR by JAG1 and its cleaved form
JICD is cell type-dependent. It also seems like HPV18 in a glandular environment is
not affected by JAG1 expression. HPV16 LCR is responsive to JAG1 and JICD
activity, although this cannot be observed in all cases. These observations could be
due to the differences in the promoter binding sites on the different LCRs (figure 3).
For example, AP-1 has 4 binding sites on HPV16 LCR and only 2 on HPV18 LCR.
Other binding sites could also be responsible for the observed effect. It has been
previously shown that HPV16 LCR harbors SOX2 binding sites not found in HPV18
53

(Martínez-Ramírez et al., 2017), and a very recent report shows that JICD can
modulate the expression of SOX2 (Kim et al., 2021).
In conclusion, the activity of HPV 16 and HPV18 LCRs can be modulated by JAG1
and JICD, and it is cell type-dependent. Our results also suggest that there is more than
one mechanism of modulation since we observed different effects from FL JAG1
compared to JICD. Thus, it would be important to determine the involvement of Notch
regarding this response since we could expect that JAG1 overexpression is promoting
Notch activation.

5.5 The modulation of the LCR by JAG1 and JICD is dose-dependent
Controversial results on the participation of the Notch pathway in cervical
carcinogenesis have been reported previously (Talora et al., 2002) (Talora et al., 2005)
(Henken et al., 2012). Henken et al. (2012) show that the effect on Notch
transcriptional regulation over HPV is dose-dependent. Thus, we look for a dosedependent effect of JAG1 and JICD in CC cell lines. Results in figure 14 show the
modulation of HPV16 and HPV18 LCRs under low concentrations of JAG1 and JICD.
The first results obtained (figure 13) were done with 800 ng of JAG1 and JICD;
meanwhile, in figure 14, the activity of the autologous LCRs of Caski, Siha, and Hela
cells was done with low expression of JAG1 and JICD (100 ng).
As it can be observed, there is no effect of lowering the concentration of JAG1 in
Caski cells (figure 14). For Siha cells, the high expression of JAG1 and JICD had no
effect (figure 13), but low concentrations of the proteins promote the activity of
HPV16 LCR (figure 14). Finally, in Hela cells which were also not responsive to high
concentrations of JAG1 or JICD (figure 13), low concentrations had no apparent effect
over the HPV18 LCR activity either (figure 14).
These results support our previous observations that HPV18 LCR is not responsive to
JAG1 or JICD in a transformed state. Remarkably, Talora et al. (2002) show that
NICD expression modulates HPV transcription in Hela cells but not in Siha or Caski
cells (Talora et al., 2002).

54

As mentioned with Hacat cells, the overexpression of JAG1 decreases HPV18 LCR
activity, although not significantly (figure 13), and Hela cells show no response at all
to JAG1 expression, we could think that the involvement of JAG1 and JICD on
cervical carcinogenesis is an early event of the transformation process. The fact that
overexpression of JAG1 FL has no effect on Hela cells, and knowing the previous
report of the involvement of NICD in Hela transcription modulation, our results could
indicate that the activation of Notch in Hela cells is not dependent on JAG1. In this
respect, it has been observed that in Caski cells that the endogenously high expression
of JAG1 is associated with low endogenous expression of Manic Fringe
(Veeraraghavalu et al., 2004), which is an important modulator of the affinity between
Notch and its ligands. Considering this, it would be interesting to determine the
expression of the Manic Fringe levels in Hela cells as well as the expression of other
Notch ligands. We have preliminary results on the expression of DLL1 in CC cell lines
(appendix, S2), which suggest a higher expression of this protein in Hela cells.

5.6 Modulation of LCR is dependent on AP-1 activity in Caski cells
The AP-1 complex is an important factor in viral oncogene expression (de Marco et
al., 2012). E.g., the Epstein Barr virus harbors AP-1 responsive sequences on its
genome (Baumann et al., 1998), and in the case of HPV16 and HPV18, they also
present AP-1 binding sites on their genome. The activation of AP-1 can be chemically
induced by Phorbol esters (TPA). This promotes AP-1 binding to the TPA response
element (TRE). To determine the effects of AP-1 transcriptional activity over LCRs
under the expression of JAG1 and JICD, cells were treated with TPA, and the
luciferase reporter gene was measured.
In figure 15, we compare the transcriptional activity of non-treated cells transfected
with JAG1 or JICD against cells transfected with the same constructs and treated with
TPA for 24 h. In Caski cells, TPA treatment had no effect on the control condition.
But the TPA treatment counteracts the increase of HPV16 LCR activity induced by
JAG1 transfected cells; meanwhile, in JICD transfected cells, the TPA treatment
increases LCR activity although not to the control levels, and not significantly. These

55

results point to the regulation of HPV LCR16 activity by JAG1 and JICD through AP1 activity.
In Siha cells, the conditions transfected only with the autologous LCR16 and
pCDNA3.1 (+) the TPA treatment increases the transcriptional activity by almost
80%; similar behavior can be observed in JAG1 and JICD overexpression. Suggesting
that JAG1 and JICD have no effect on the LCR, neither related to the AP-1 activity.
Finally, in Hela cells, the treatment with TPA decreases the transcription of the
autologous HPV18 LCR in the control condition as well as when overexpressing
JAG1 and JICD, suggesting no involvement of these proteins in the regulation of the
LCR.
As mentioned before in figure 3, HPV16 LCR harbors 4 AP-1 binding sites;
meanwhile, HPV18 LCR only has 2 binding sites for AP-1 (O’Connor et al., 1996)
(Steger & Corbach, 1997). This difference could be expected to have an impact on the
regulation of transcriptional activity under the influence of TPA. Although Caski and
Siha cells are both HPV16 positive, they behave differently, suggesting that other
factors participate in the observed modulation in Caski cells.
Similar to the effect of NICD over AP-1 activity, which is known to be cell typedependent (Talora et al., 2002), we also observed that behavior with JAG1 and JICD.
Of note, the modulation of HPV16 LCR in Caski cells is different between JAG1 and
JICD. JAG1 promotes activity; meanwhile, JICD decreases activity, an effect that is
attenuated by AP-1 activation through TPA treatment. These results also suggest that
JAG1 and its cleaved form have opposite activities, although both are affected by AP1 activation. This could suggest that AP-1 transcriptional activation of viral genes has
an effect on JAG1 and JICD. When it comes to the viral oncoproteins E6 and E7,
several biding partners have been reported (Tungteakkhun & Duerksen-Hughes,
2008). E6 is able to bind to PDZ (PSD-95/Dlg/Zo-1) containing proteins and mark
them for degradation (Van Doorslaer et al., 2015). Interestingly, JAG1 has a Cterminal PDZ protein binding motif that has been poorly studied (Ascano et al., 2003).
There is a possibility that E6 is degrading binding partners of JAG1 and indirectly
modulating the observed regulation of LCR in our system. Thus, it would be

56

interesting to evaluate the modulation of LCR by JAG1 and JICD lacking the PDZ
binding motifs.

5.7 CC cells express different protein levels of the AP-1 transcription
factor components
There is evidence that supports that changes in the AP-1 complex composition could
affect the tumorigenicity of the cells. Henken et al. (2012) claim that high Notch
expression changes the AP-1 composition from c-Jun/c-Fos homodimer to the nontumorigenic c-Jun/c-Fra form (Henken et al., 2012). We next evaluated the
endogenous expression of c-Jun, c-Fos, and c-Fra in the CC cell lines.
As observed in figure 16, the expression of c-Jun is around the same in all the cell
lines studied. This is expected since c-Jun is the main component of the AP-1 complex,
meaning that it is always present either as a homodimer or heterodimer with either cFos or c-Fra (Garces de Los Fayos Alonso et al., 2018). In the case of c-Fos, it is
remarkable the fact that Caski cells present a very low amount of the protein. It has
previously been reported that Caski and Siha cells have an integration on their c-Fra
encoding region, so they have a lower expression of this component (Talora et al.,
2002). However, the expression of c-Fos in our Siha cells is significantly higher than
Caski. C-Fra is similarly expressed in all the transformed cell lines, and a higher
expression was observed in the non-tumorigenic cell line Hacat. An expected result
since it is known that the c-Jun/c-Fra dimer is related to non-tumorigenic behavior
(Henken et al., 2012).
The differences in the AP-1 components observed in our cell lines could also be
accountable for the differences we observed in the activity of the HPV16 and HPV18
LCRs (appendix, S1). It is interesting that we can observe an effect of JAG1 and JICD
overexpression on LCR activity in Caski cells, which turns out to be the ones with less
c-Fos.

57

5.8 JAG1 binds to c-Jun in Caski cells
By doing Co-IP, we confirmed an interaction between c-Jun and JAG1 in CC cells
(figure 19 & 20). In the input samples, there can be seen a band at the corresponding
size for c-Jun (43, 48 kDa) and also in immunoprecipitated samples. Even when we
include all the cell lines studied here, we could just determine the interaction between
c-Jun and JAG1 in Caski cells. This interaction could explain the modulation observed
over LCR activity under JAG1 expression. To determine if the interaction is exclusive
to JICD or if it the occurrence is through a domain only found on JAG1 FL, we
overexpressed JAG1 and JICD in the C33A cell line, which has a low expression of
endogenous JAG1. In figure 21, we observe that c-Jun binds to both forms of JAG1.
It is important to mention that the results need to be further addressed since C33A is
not negative to endogenous JAG1 expression (figure 9), the background levels of the
protein could be masking the observations. This is crucial since LaVoie & Selkoe.
(2003) mentions that the modulation of AP-1 is dependent on the JICD (LaVoie &
Selkoe., 2002). Previous work has suggested an interaction between JICD and AP-1
(Hye Jin Lee et al., 2015). The interaction of JICD with Fe65 can promote nuclear
translocation of JICD and bind to the AP-1 complex. With the results obtained here,
we cannot conclude if JICD directly binds to c-Jun or as a part of a complex. We also
have no evidence where this interaction in the cell takes place. A plausible hypothesis
would be that c-Jun and JICD are interacting in the cytoplasm, which could be
blocking the nuclear translocation of c-Jun, thus decreasing the activity of LCR.

5.9 JICD decrease the proliferation of Caski and Hela cells
After showing that JAG1 and JICD can modulate the LCRs and that his effect is dosedependent and also depending on AP-1 activity, we proceeded to investigate the
proliferation rates of the CC cells. The autologous LCR and pCDNA3.1 (+) was used
as a control, and JAG1 and JICD were overexpressed in the system. The results seen
in figure 23 show that in Caski cells, JICD decreases the proliferation compared with
the control. The proliferation of JAG1 transfected cells was the highest but not
significantly higher than the empty vector. The proliferation decreased in Hela cells
transfected with JICD as well as when compared to the pCDNA3.1 (+) condition.
58

When these cells were transfected with JAG1, it caused a small decrease of
proliferation compared to the control, although it was not significant.
These results confirm our observations on LCR modulation by JAG1 and JICD. The
proliferation and the transcriptional activity (figure 13) decrease in Caski cells when
overexpressing JICD. Thus, it would be necessary to evaluate the expression of E6
and E7 in these same conditions. Also, evaluating the targets of the viral oncoproteins
p53 and pRB would be interesting. The results presented here point to a protective
effect of JICD against HPV infection.
Further evaluation on the participation of JAG1 and its cleaved form on viral
transcription regulation need to be done. Here we present evidence that suggests that
JAG1 is cleaved in CC cell lines. The overexpression of JAG1 and JICD modulates
the activity of HPV16 and HPV18 LCRs depending on cell type, and JAG1 can bind
to c-Jun. Although the participation of Notch was not addressed, this should also be
evaluated.

5.10 Concluding summary
1. JAG1 is processed in the CC derived cell lines.
2. The processing of JAG1 in CC cell lines is mediated through γ-secretase.
3. JAG1 and JICD can modulate the activity of the HPV 16 and 18 LCRs in a context
depending manner.
4. The impact of JAG1 and JICD on HPV modulation is concentration dependent
5. JAG1 and JICD interacts with c-Jun in Caski cells.

59

6. References:

Abraham, O. S. J., Miguel, T. S., Inocencio, H. C., & Blondy, C. C. (2017). A quick
and effective in-house method of DNA purification from agarose gel, suitable
for sequencing. 3 Biotech. https://doi.org/10.1007/s13205-017-0851-1
Alberts, B. (2013). Molecular Biology of the Cell 6th Edition. In Journal of
Chemical Information and Modeling.
Arbyn, M., Weiderpass, E., Bruni, L., de Sanjosé, S., Saraiya, M., Ferlay, J., & Bray,
F. (2020). Estimates of incidence and mortality of cervical cancer in 2018: a
worldwide analysis. The Lancet Global Health. https://doi.org/10.1016/S2214109X(19)30482-6
Ascano, J. M., Beverly, L. J., & Capobianco, A. J. (2003). The C-terminal PDZligand of JAGGED1 is essential for cellular transformation. Journal of
Biological Chemistry. https://doi.org/10.1074/jbc.M211427200
Azimi, M., & Brown, N. L. (2019). Jagged1 protein processing in the developing
mammalian lens. Biology Open. https://doi.org/10.1242/bio.041095
Baumann, M., Mischak, H., Dammeier, S., Kolch, W., Gires, O., Pich, D., Zeidler,
R., Delecluse, H.-J., & Hammerschmidt, W. (1998). Activation of the EpsteinBarr Virus Transcription Factor BZLF1 by 12-O-Tetradecanoylphorbol-13Acetate-Induced Phosphorylation. Journal of Virology.
https://doi.org/10.1128/jvi.72.10.8105-8114.1998
Brown, T. A. (2006). GENE CLONING AND DNA ANALYSIS. In an
introduction.
Burd, E. M. (2003). Human papillomavirus and cervical cancer. In Clinical
Microbiology Reviews. https://doi.org/10.1128/CMR.16.1.1-17.2003
Chamchoy, K., Pakotiprapha, D., Pumirat, P., Leartsakulpanich, U., & Boonyuen, U.
(2019). Application of WST-8 based colorimetric NAD(P)H detection for
quantitative dehydrogenase assays. BMC Biochemistry.
https://doi.org/10.1186/s12858-019-0108-1
Counts, S. E. (2010). Western Blot. In Encyclopedia of Movement Disorders.
https://doi.org/10.1016/B978-0-12-374105-9.00297-5
D’Souza, B., Meloty-Kapella, L., & Weinmaster, G. (2010). Canonical and non-

60

canonical notch ligands. In Current Topics in Developmental Biology.
https://doi.org/10.1016/S0070-2153(10)92003-6
de Marco, F., Bucaj, E., Foppoli, C., Fiorini, A., Blarzino, C., Filipi, K., Giorgi, A.,
Schininà, M. E., Di Domenico, F., Coccia, R., Butterfield, D. A., & Perluigi, M.
(2012). Oxidative stress in HPV-driven viral carcinogenesis: Redox proteomics
analysis of HPV-16 dysplastic and neoplastic tissues. PLoS ONE.
https://doi.org/10.1371/journal.pone.0034366
Duodecim, K. O. (2020). Kohdunkaulan syöpä.
https://www.terveyskirjasto.fi/terveyskirjasto/tk.koti?p_artikkeli=dlk00144
Forghany, Z., Robertson, F., Lundby, A., Olsen, J. V., & Baker, D. A. (2018).
Control of endothelial cell tube formation by Notch ligand intracellular domain
interactions with activator protein 1 (AP-1). Journal of Biological Chemistry.
https://doi.org/10.1074/jbc.M117.819045
Gallagher, S. R. (2012). SDS-polyacrylamide gel electrophoresis (SDS-PAGE).
Current Protocols in Essential Laboratory Techniques.
https://doi.org/10.1002/9780470089941.et0703s06
Garces de Los Fayos Alonso, I., Liang, H. C., Turner, S. D., Lagger, S., Merkel, O.,
& Kenner, L. (2018). The role of activator protein-1 (AP-1) family members in
CD30-positive lymphomas. In Cancers.
https://doi.org/10.3390/cancers10040093
Grochowski, C. M., Loomes, K. M., & Spinner, N. B. (2016). Jagged1 (JAG1):
Structure, expression, and disease associations. In Gene.
https://doi.org/10.1016/j.gene.2015.10.065
Gupta, S., Kumar, P., & Das, B. C. (2018). HPV: Molecular pathways and targets. In
Current Problems in Cancer.
https://doi.org/10.1016/j.currproblcancer.2018.03.003
Henken, F. E., Arce, J. D. C., Rösl, F., Bosch, L., Meijer, C. J. L. M., Snijders, P. J.
F., & Steenbergen, R. D. M. (2012). The functional role of Notch signaling in
HPV-mediated transformation is dose-dependent and linked to AP-1 alterations.
Cellular Oncology. https://doi.org/10.1007/s13402-011-0062-4
Hoseini, S. S., & Sauer, M. G. (2015). Molecular cloning using polymerase chain
reaction, an educational guide for cellular engineering. Journal of Biological
Engineering. https://doi.org/10.1186/1754-1611-9-2
Ikeuchi, T., & Sisodia, S. S. (2003). The Notch ligands, Delta1 and Jagged2, are
61

substrates for presenilin-dependent “γ-secretase” cleavage. Journal of
Biological Chemistry. https://doi.org/10.1074/jbc.C200711200
Islam, M. S., Aryasomayajula, A., & Selvaganapathy, P. R. (2017). A review on
macroscale and microscale cell lysis methods. In Micromachines.
https://doi.org/10.3390/mi8030083
Kim, E.-J., Kim, J. Y., Kim, S.-O., Ham, S. W., Choi, S.-H., Hong, N., Park, M. G.,
Jang, J., Seo, S., Lee, K., Jeong, H. J., Kim, S. J., Jeong, S., Min, K., Kim, S.C., Jin, X., Kim, S. H., Kim, S.-H., & Kim, H. (2021). JAG1 intracellular
domain acts as a transcriptional cofactor that forms an oncogenic transcriptional
complex with DDX17/SMAD3/TGIF2. BioRxiv, 2021.03.31.437839.
https://doi.org/10.1101/2021.03.31.437839
Kopan, R., & Ilagan, M. X. G. (2009). The Canonical Notch Signaling Pathway:
Unfolding the Activation Mechanism. In Cell.
https://doi.org/10.1016/j.cell.2009.03.045
Kwon, S. M., Alev, C., Lee, S. H., & Asahara, T. (2012). The molecular basis of
notch signaling: A brief overview. In Advances in Experimental Medicine and
Biology. https://doi.org/10.1007/978-1-4614-0899-4_1
Landais, I., Vincent, R., Bouton, M., Devauchelle, G., Duonor-Cerutti, M., &
Ogliastro, M. (2006). Functional analysis of evolutionary conserved clustering
of bZIP binding sites in the baculovirus homologous regions (hrs) suggests a
cooperativity between host and viral transcription factors. Virology.
https://doi.org/10.1016/j.virol.2005.08.036
LaVoie, M. J., & Selkoe, D. J. (2003). The Notch Ligands, Jagged and Delta, Are
Sequentially Processed by α-Secretase and Presenilin/γ-Secretase and Release
Signaling Fragments. Journal of Biological Chemistry.
https://doi.org/10.1074/jbc.M302659200
Lee, Ho Jin, & Zheng, J. J. (2010). PDZ domains and their binding partners:
Structure, specificity, and modification. In Cell Communication and Signaling.
https://doi.org/10.1186/1478-811X-8-8
Lee, Hye Jin, Yoon, J. H., Ahn, J. S., Jo, E. H., Kim, M. Y., Lee, Y. C., Kim, J. W.,
Ann, E. J., & Park, H. S. (2015). Fe65 negatively regulates Jagged1 signaling
by decreasing Jagged1 protein stability through the E3 ligase Neuralized-like 1.
Biochimica et Biophysica Acta - Molecular Cell Research.
https://doi.org/10.1016/j.bbamcr.2015.08.009
62

Liebler, S. S., Feldner, A., Adam, M. G., Korff, T., Augustin, H. G., & Fischer, A.
(2012). No Evidence for a Functional Role of Bi-Directional Notch Signaling
during Angiogenesis. PLoS ONE. https://doi.org/10.1371/journal.pone.0053074
Lim, K. J., Brandt, W. D., Heth, J. A., Muraszko, K. M., Fan, X., Bar, E. E., &
Eberhart, C. G. (2015). Lateral inhibition of Notch signaling in neoplastic cells.
Oncotarget. https://doi.org/10.18632/oncotarget.2762
Lizano, M., Berumen, J., Guido, M. C., Casas, L., & García-Carranca, A. (1997).
Association between human papillomavirus type 18 variants and histopathology
of cervical cancer. Journal of the National Cancer Institute.
https://doi.org/10.1093/jnci/89.16.1227
Martínez-Ramírez, I., del-Castillo-Falconi, V., Mitre-Aguilar, I. B., Amador-Molina,
A., Carrillo-García, A., Langley, E., Zentella-Dehesa, A., Soto-Reyes, E.,
García-Carrancá, A., Herrera, L. A., & Lizano, M. (2017). SOX2 as a new
regulator of HPV16 transcription. Viruses. https://doi.org/10.3390/v9070175
Merilahti, J. A. M., Ojala, V. K., Knittle, A. M., Pulliainen, A. T., & Elenius, K.
(2017). Genome-wide screen of gamma-secretase-mediated intramembrane
cleavage of receptor tyrosine kinases. Molecular Biology of the Cell.
https://doi.org/10.1091/mbc.E17-04-0261
O’Connor, M. J., Tan, S. H., Tan, C. H., & Bernard, H. U. (1996). YY1 represses
human papillomavirus type 16 transcription by quenching AP-1 activity.
Journal of Virology. https://doi.org/10.1128/jvi.70.10.6529-6539.1996
O’Leary, J. J., White, C., Spillane, C., Naik, P., O’Brien, R., Reynolds, S., Pham, T.,
Pilkington, L., Sharkey Ochoa, I., Bolger, N., Barry O’Crowley, J., Tewari, P.,
O’Toole, S., Sweeney, M., Keegan, H., Normand, C., Sharp, L., Flannelly, G.,
& Martin, C. (2018). Cervical screening: A new way forward (tests of risk and
tests of disease). HRB Open Research.
https://doi.org/10.12688/hrbopenres.12794.1
Organista-Nava, J., Gómez-Gómez, Y., Garibay-Cerdenares, O. L., Leyva-Vázquez,
M. A., & Illades-Aguiar, B. (2019). Cervical cancer stem cell-associated genes:
Prognostiimplications in cervical cancer. In Oncology Letters.
https://doi.org/10.3892/ol.2019.10307
Ottinger, M., Smith, J. A., Schweiger, M. R., Robbins, D., Powell, M. L. C., You, J.,
& Howley, P. M. (2009). Cell-type specific transcriptional activities among
different papillomavirus long control regions and their regulation by E2.
63

Virology. https://doi.org/10.1016/j.virol.2009.09.027
Pelullo, M., Quaranta, R., Talora, C., Checquolo, S., Cialfi, S., Felli, M. P., Kronnie,
G., Borga, C., Besharat, Z. M., Palermo, R., Di Marcotullio, L., Capobianco, A.
J., Gulino, A., Screpanti, I., & Bellavia, D. (2014). Notch3/Jagged1 circuitry
reinforces notch signaling and sustains T-ALL. Neoplasia (United States).
https://doi.org/10.1016/j.neo.2014.10.004
Ribeiro, A. L., Caodaglio, A. S., & Sichero, L. (2018). Regulation of HPV
transcription. In Clinics. https://doi.org/10.6061/clinics/2018/e486s
Schiffman, M., Castle, P. E., Jeronimo, J., Rodriguez, A. C., & Wacholder, S.
(2007). Human papillomavirus and cervical cancer. In Lancet.
https://doi.org/10.1016/S0140-6736(07)61416-0
Steger, G., & Corbach, S. (1997). Dose-dependent regulation of the early promoter
of human papillomavirus type 18 by the viral E2 protein. Journal of Virology.
https://doi.org/10.1128/jvi.71.1.50-58.1997
Talora, C., Cialfi, S., Segatto, O., Morrone, S., Kim Choi, J., Frati, L., Dotto, G. P.,
Gulino, A., & Screpanti, I. (2005). Constitutively active Notch1 induces growth
arrest of HPV-positive cervical cancer cells via separate signaling pathways.
Experimental Cell Research. https://doi.org/10.1016/j.yexcr.2005.01.015
Talora, C., Sgroi, D. C., Crum, C. P., & Paolo Dotto, G. (2002). Specific downmodulation of Notch1 signaling in cervical cancer cells is required for sustained
HPV-E6/E7 expression and late steps of malignant transformation. Genes and
Development. https://doi.org/10.1101/gad.988902
Tripathi, R., Rath, G., Hussain, S., Jawanjal, P., Bandil, K., Sharma, V., Bharadwaj,
M., & Mehrotra, R. (2018). Jagged-1 induced molecular alterations in HPV
associated invasive squamous cell and adenocarcinoma of the human uterine
cervix. Scientific Reports. https://doi.org/10.1038/s41598-018-27699-1
Tungteakkhun, S. S., & Duerksen-Hughes, P. J. (2008). Cellular binding partners of
the human papillomavirus E6 protein. In Archives of Virology.
https://doi.org/10.1007/s00705-007-0022-5
Van Doorslaer, K., DeSalle, R., Einstein, M. H., & Burk, R. D. (2015). Degradation
of Human PDZ-Proteins by Human Alphapapillomaviruses Represents an
Evolutionary Adaptation to a Novel Cellular Niche. PLoS Pathogens.
https://doi.org/10.1371/journal.ppat.1004980
Veeraraghavalu, K., Pett, M., Kumar, R. V., Nair, P., Rangarajan, A., Stanley, M. A.,
64

& Krishna, S. (2004). Papillomavirus-Mediated Neoplastic Progression Is
Associated with Reciprocal Changes in Jagged1 and Manic Fringe Expression
Linked to Notch Activation. Journal of Virology.
https://doi.org/10.1128/jvi.78.16.8687-8700.2004

65

7. Appendices
7.1 Supplementary figures

66

Figure S1. Renilla Luciferase reporter assay shows the promoter activities of HPV16 and HPV18
under JAG1 and JICD overexpression. Cells were transfected with 100 ng of HPV16 or HPV18 LCR
reporter plasmids, 800 ng of JAG1/JICD plasmid, 100 ng of Renilla plasmid, and for negative controls,
800 ng of empty vector pcDNA3.1 (+). 24 h after transfection, the cells were lysed, and luminescence
activity was measured. ANOVA analysis was done to determine statistical significance. Data represent
the mean of three independent experiments, each performed in triplicate. RLU= Relative Light Unit.

Figure S2. DLL1 endogenous expression in CC cell lines. Western blot image of Dll1 expression in
CC cells. β-actin was used as a loading control.

67

8. Svensk sammanfattning
Introduktion
Cancer är en kategori av sjukdomar som kännetecknas av oregelbunden celltillväxt
som kan invadera och sprida sig i kroppen. Cancer är inte en smittsam sjukdom i sig,
och majoriteten av fallen har inga smittsamma spår. 15 % av cancer hos människor
antas orsakas av mekanismer som involverar virus, bakterier eller parasiter (Alberts,
2013). Livmoderhalscancer är den fjärde vanligaste cancertypen hos kvinnor över hela
världen (Arbyn et al., 2020). År 2018 fanns det 570 000 fall av livmoderhalscancer
och 310 000 dödsfall av sjukdomen, Kina och Indien ensamma stod för över en
tredjedel av världens livmoderhalscancer fall. I Finland är livmoderhalscancer den
tredje vanligaste av gynekologiska cancerformer. Det diagnostiseras 150–175 fall
årligen och det upptäcks oftast hos kvinnor i åldrarna 30-39 (Duodecim, 2020)
HPV delas ofta in i hög- och lågriskfaktorer beroende på deras förmåga att orsaka
cancer (Ribeiro et al., 2018). Högriskvarianter, såsom HPV16 och 18, står för cirka 55
% av invasiva cervikalcancerformer, medan lågriskvarianter som HPV6 och 11
ansvariga för över 90 % av könsvårtor som uppstår i könsorgan. Det finns mer än 100
HPV-typer och cirka 30 av dem är associerade med skador på könsorgan (Ottinger et
al., 2009). Papillomvirus (PV) tillhör de icke-omslutna virus typen som har cirkulärt,
dubbelsträngat DNA. Genomet innehåller cirka 8000 baspar (bp) (Ribeiro et al., 2018)
och är uppdelat i tre regioner: Den långa kontrollregionen, den tidiga och den sena
regionen.
Den icke-kodande LCR ligger mellan L1- och E6-generna. Det finns olika motiv som
kan binda till LCR och antingen aktivera eller undertrycka viraltranskriptionen. Ett av
dessa motiv är transkriptionsfaktorn, Aktivator Protein-1-komplexet (AP-1). LCR i
HPV-genomet har AP-1-bindningsställen i promotor- och förstärkningsregionen och
AP-1 är associerad bland annat med transkriptionskontrollsystemet (Talora et al.,
2002) och många andra biologiska processer. AP-1-komplexet består av en
heterodimer med kombinationen av c-Jun- och antingen c-Fos- eller c-Fra-proteiner.
AP-1-komplexet har en viktig roll i regleringen av virusets onkogenutrryck.
68

Notch-signalkaskaden är en av de mest evolutionärt bevarade signalvägarna (Kwon et
al., 2012). Notch är involverat i många biologiska processer, allt från att
upprätthållande av stamceller, vävnadsutveckling till att upprätthålla homeostas. Både
onormala uppregleringar och nedregleringar av Notch-signalering kan leda till
utvecklingsavvikelser och cancer, därför är en exakt reglering av Notch-aktivitet
nödvändig för normal cellfunktion.
JAG1 tillhör familjen Serrate / Jagged (DSL) proteiner kända för sig roll som Notchligander (Ascano et al., 2003). JAG1-mutationer har kopplats till olika former av
sjukdomar (Grochowski et al., 2016). JAG1 har en kort intracellulär domän (ICD), en
transmembrandomän och en längre extracellulär domän (ECD). JAG1 har många
motiv som säkerställer proteinets korrekta funktion, en N-terminal region, och en
mycket konserverad DSL-domän, EGF-upprepningar och ett område rikt på cysteiner
(figur 4). För att JAG1 ska binda till Notch-receptorn behövs DSL-domänen och EGFupprepningarna ökar affiniteten för bindningen (Grochowski et al., 2016).
JAG1 har visat främja onkogena funktioner genom att öka Notch-signalvägen i olika
former av cancer (Lee et al., 2015). JAG1 klyvs av a- och y-sekretaser. Denna
mekanism leder till frisläppandet av JICD, som kan translokeras in i kärnan med hjälp
av kärnlokaliseringssignaler och på så sätt påverkar genuttrycket.
I den här magisteravhandlingen undersöktes huruvida JAG1 prosesseras i
livmoderhalscancer celler och om det kan påverka transkriptionen av HPV. Det
undersöktes även via vilken interraktion som detta äger rum.

69

Material och metoder
För att kunna undersöka förhållandet mellan AP-1 komplexet och Jagged1 (JAG1)
proteinet i livmoderhalscancer användes olika metoder som kartlägger interraktioner
och gentranskriptionsnivåer i cellerna. Interraktionen studeras i cell linjer från olika
typers livmoderhalscancer för att kartlägga skillnader mellan livmoderhalscancer som
är positiva för HPV16 eller HPV18 eller helt saknar infektion av HPV. Metoder såsom
kloning, tranfektion, western blot, luciferas,olika överlevnadsanalyser och
immunoprecipitering användes för att undersöka AP-1s roll i livmoderhalscancer.

Kloning
Kloning är en metod som görs för att konstruera flera kopior av en gen av intresse.
Det främmande DNA:t sätts in i en plasmid, en cirkulär DNA-bärare som isolerats
från bakterier. Plasmider innehåller en eller flera essentiella gener för värdbakterien,
såsom antibiotikaresistens (Brown, 2006). Plasmider har DNA-sekvenser som
fungerar som replikationsursprunget (ORI), vilket gör det möjligt för plasmidgenerna
att multiplicera i bakterier. Om en gen framgångsrikt har införts i plasmiden, kan
plasmiden odlas i koloner av bakterier som självständigt multiplicerar genen.
Kloningsplasmiden eller -vektorn, behandlas med ett restriktionsenzym som klyver
DNA där det främmande DNA:t sätts in (Brown, 2006). Restriktionsenzymen måste
väljas på lämpligt sätt för att säkerställa korrekta positionssnitt, så att inte det
främmande DNA:t som kommer att införas klyvs. HindIII, som känner igen
AAGCTT-sekvensen, och Xbal, som känner igen TCTAGA-sekvensen, är exempel
på restriktionsenzymer som används för att klona DNA. Många restriktionsenzymer
klyver det dubbelsträngade DNA:t i mitten av sekvensen som den känner igen, vilket
resulterar i en trubbig ände, medan andra inte skär DNA på samma plats i de två DNAsträngarna; utan istället resulterar i ett överhäng i båda ändarna och dessa kallas för
"klibbiga" ändar.

70

Kloningsprocessens sista steg är att ligera ihop plasmiden med genen av intresse.
Denna process kallas för ligering, och det katalyseras av enzymet DNA-ligas som
limmar ihop den introducerade DNA-sekvensen in i plasmiden (Brown, 2006). Efter
en lyckad ligering kan man introducera plasmiden innehållande målgenen till bakterier
som tar upp plasmiden och börjar multiplicera den så att man kan erhålla en större
mängd av genen för att sedan till exempel transfektera in genen i celler för att
utrryckas.

Tranfektion
Transfektion är en metod som används för att införa nukleinsyror (DNA) i eukaryota
celler med olika kemiska eller fysiska metoder. Den införda nukleinsyrasekvensen
kodar för en gen som cellerna ska uttrycka. I denna avhandling introducerar jetPRIME
DNA-transfektionsreagens från Polyplus-transfektion främmande DNA i cellerna.
Huvudmålet vid transfektion är att generera rekombinanta proteiner eller att hämma
eller förbättra genuttryck. Således är transfektion en kraftfull metod för att analysera
funktionen eller regleringen av gener eller proteiner.
Plasmidvektorer eller mRNA kan användas för att införa främmande genetiskt
material i eukaryota celler. Uttrycket av den önskade målgenen och dess
proteinprodukt kan uppnås med hjälp av rekombinanta proteiner, och sålunda kan det
uttryckta

proteinet

produceras

med

korrekt

tertiärstruktur

och

posttranslationsmodifieringar (PTM) som behövs. Om en detekterbar markör läggs till
proteinet av intresse kan man studera promotorer, förstärkare eller protein-proteininteraktioner.
FuGENE® HD-transfektionsreagens användes för att transfektera livmoderhalscancer
celler. Rätt mängd DNA som skulle tillsättas beräknades enligt plasmidernas
koncentration och de rekommenderade mängderna i FuGENE-protokollet. En dag före
transfektion beräknades cellerna och pläterades enligt protokollet så att cellerna var
ungefär 80% konfluenta. I ett Eppendorf-rör blandades DNA:t som skulle
transfekteras,

FuGENE®

HD-transfektionsreagens

och

OPTIMEM-media

inkuberades vid rumstemperatur under 10 minuter. Efter detta pipetterades

71

blandningen till plattan och blandades försiktigt. Plattan inkuberades under 24-72
timmar i en 37 ° C cellinkubator.

Western blottning (WB)
Western blottning (WB) är en metod som används för att kunna kvantifiera proteiner
som

uttrycks

i

celler.

polyakrylamidgelelektrofores

WB

metoden

(SDS-PAGE),

består

av

överföring

av

flera

delsteg;

protein

till

nitrocellulosamembran och immunoblottning. SDS-PAGE separerar proteiner i en
polyakrylamidgel baserad på proteinernas storlek med hjälp av elektrisk spänning.
Efter separationen kan proteinerna överföras till ett nitrocellulosamembran som har
hög affinitet för proteiner. Membranet med proteinerna kan därefter inkuberas
tillsammans med primära antikroppar som binder till målproteiner. Sekundära
antikroppar som är kopplade till en reportermolekyl, kan sedan användas för att
detektera proteinerna med diverse metoder.
Nitrocellulosamembranet blottades med specifika primära antikroppar för Jagged1
och

dess

interaktionspartners.

För

att

detektera

proteinerna

användes

reportermolekylen pepparrotsperoxidas som är länkade till den sekundära
antikroppen. En kemiluminiscenslösning tillsattes på membranet för detektionen av
proteinerna. En oxidationsreaktion mellan pepparrotsperoxidaset och luminolet i
kemiluminiscenslösningen med biprodukt ljusemission kan sedan detekteras med
tillexempel en framkallningsmaskin som kan visualisera membranet och proteinerna
av intresse.

Renilla Luciferas reporteranalys
Renilla

luciferas

reporteranalys

används

för

att

studera

genuttryck

på

transkriptionsnivå. Analysen används för att mäta genexpressionen av en klonad gen,
som är sammansmält med den DNA-kodande sekvensen för Renillaluciferas. Om
proteinet reglerar målgenen kommer cellerna att uttrycka luciferas. Om proteinet
nedreglerar målgenuttrycket kommer cellerna att uttrycka mindre luciferas. Luciferas
är ett monomert protein som härrör från eldflugan Photinus Pyralis. Det är detta

72

protein som används som en reportervektor för genuttryck. Den katalytiska reaktionen
drivs av syre, luciferin och energi omvandlad till oxyluciferin och ljusenergi.
Ljusenergin kan mätas med en luminometer, vilket ger en kvantitativ avläsning av
systemet. Ljusenergin som emitteras är direkt proportionell mot mängden genuttryck
för målgenen.
För att normalisera transfektionsvärdena används en kontrollreporter. För att göra
detta transfekteras en plasmid innehållande DNA-kodande sekvensen för Renilla som
agerar som kontrollreportern. Renilla avläsningen visar nivån av transfektion i cellerna
och detta kan användas för att normalisera transfektionvärden i systemet.
Cellerna tvättades försiktigt med rumstempererat PBS. 75 μl Dual-Glo® Luciferaseanalysreagens tillsattes till varje brunn och plattan inkuberades vid rumstemperatur i
30 minuter, varefter Luciferas luminiscens mättes med en luminometer. Efter
mätningen tillsattes Dual-Glo® Stop & Glo®-reagenset till plattan och plattan
inkuberades igen under 10 minuter i tumstemperatur. Efter inkubationen mättes
Renillaluminiscens med samma luminometer. Efter mätningarna beräknades
förhållandet Luciferas-: Renillaluminiscens för varje brunn och proverna
normaliserades till förhållandet från en serie av kontrollbrunnar.

Koimmunoprecipitering (IP)
Immunoprecipitering

(IP)

är

en

teknik

som

används

för

att

kartlägga

proteininteraktioner i celler. Detta görs genom att behandla cellysat med en antikropp
som känner igen proteinet av intresset, och proteiner som interragerar med det. I
cellsysat är alla proteiner som uttrycks i systemet närvarande, och genom IP är det
möjligt att isolera och koncentrera protein från suspensionen.
Antikropp-proteinkomplexet separeras genom en antigenbindande struktur, såsom
sefarospärlorna som är bundna till antikroppen. Interaktionen mellan antikroppen och
proteinkomplexet kan sedan detekteras med WB. Pärlorna är belagda med ett protein
som binder med hög affinitet till antikroppar, vilket möjliggör interaktion.

73

Koimmunoprecipitering görs för att se om en protein-protein-interaktion är
närvarande genom att analysera precipiterade samplen med WB.
I detta projekt inkuberades livmoderhalscancer cellysat med antikroppar för JAG1
(28H8, Cell Signaling; #2620) och c-Jun, Cell Singaling (60A8). Cellysaten med
antikoppen behandlades sedan med sefarospärlor som binder till antikroppen. Genon
centrifugering separerades sefarospärlorna, varefter de kokades för att frigöra
proteinerna. Proteinlysatet JAG1 och dess interaktionspartners analyserade med WB
och blottades med antikroppar mot JAG1:s interaktionspartners såsom c-Jun.

74

Resultat och diskussion
Livmoderhalscancer är den fjärde vanligaste cancertypen hos kvinnor över hela
världen (Abryn et al., 2020). Globalt år 2018 fanns det 570 000 fall av
livmoderhalscancer och 310 000 dödsfall. Livmoderhalscancer uppstår på grund av en
ihållande infektion med HPV som är en sexuellt överförbar patogen. HPV är relaterat
till många cancertyper, såsom livmoderhals, anal, penis och vaginal bland många.
HPV typerna är uppdelade i hr- och lr-typer beroende på deras förmåga att framkalla
cancer (Ribeiro et a., 2018) Hr-varianter, såsom HPV16 och 18, är ansvariga för ca.
55% av invasiva skivepitelcancer (ISCC).
Det finns över 100 typer av HPV och ca 30 är associerade med könsorganskador
(Ottinger et al., 2009). HPV-genomet är uppdelat i tre regioner: Den långa
kontrollregionen (LCR), de tidiga (E) och de sena uttrycksregionerna (L)
(Chakravorty & Sugden, 2018). HPV-karcinogenes beror främst på E6- och E7onkoproteiner. När episomalt HPV är integrerat ökar onkoproteinerna E6- och E7uttrycket och blockerar tumörundertryckarna p53 respektive pRB, vilket leder till
cellulär transformation (Organista-Nava et al., 2019). Således är reglering av viralt
onkogenesuttryck viktigt för tumörinitiering.
JAG1 är medlem i Delta / Serrate / Lag-2 (DSL) -familjen av proteiner kända som
Notch-ligander (Ascano et al., 2003). Deltagandet av JAG1 i cervikal karcinogenes
har studerats dåligt. Bearbetningen av JAG1 och eventuella återverkningar på AP-1 i
livmoderhalscellinjer hade inte forskats i. HPV varianter har olika antal
bindningsställen för AP-1 på sina LCR (figur 3) (O'Connor et al., 1996) (Steger &
Corbach, 1997); sålunda kan samspelet mellan JAG1 och AP-1 vara ett väsentligt sätt
för HPV-transkriptionsreglering. Eftersom det finns förslag på att JAG1 och dess
klyvda former kan ha ett synergistiskt samspel med HPV (Tripathi et al., 2018) är det
viktigt att undersöka rollen av JAG1 i livmoderhalscancer och dess roll i AP-1aktivitet
Deltagandet av Notch1 och NICD i livmoderhalscancerceller har studerats ingående,
men med motstridiga resultat (Talora et al., 2002) (Talora et al., 2005) (Henken et al.,
75

2012). Talora et al. (2002) visar att i Hela-celler hämmar Notch1 cellproliferation
genom nedmodulering av E6- och E7-onkogenerna (Talora et al., 2002). Gruppen
visade också att moduleringen av AP-1 genom NICD inte är en standardmekanism i
alla livmoderhalscancercellinjer (Talora et al., 2005). Som motsats till detta föreslår,
Henken et al. (2012) att effekten av Notch över AP-1-modulering är dosberoende och
att måttliga nivåer av Notch-expression ökar AP-1-aktivitet, vilket leder till en
onkogen effekt i livmoderhalscancerceller (Henken et al., 2012). De visar att förhöjda
nivåer

av

Notch-expression

i

livmoderhalscancerceller

förändrar

AP-1-

komponenternas sammansättning från c-Jun / cFos till den icke-tumörgena c-Jun / cFra-varianten.
Eftersom deltagandet av JAG1 i cervikal karcinogenes hade studerats dåligt använder
vi i detta projekt cellinjer från livmoderhalscancer för att bestämma bearbetningen av
JAG1-protein och moduleringen av HPV: s LCR med JAG1- och JICD-proteiner.
Dessutom bedömde vi interaktionen mellan JAG1 och JICD med AP-1-element.
Resultaten som presenteras i detta arbete visar att JAG1-proteinet klyvs i
livmoderhalscancercellinjer. Vi presenterar också bevis för att aktiviteten hos HPV16
och HPV18 LCR moduleras av överuttrycket av JAG1 eller JICD, med skillnader
avseende celltyp. Vi undersökte möjligheten att HPV LCR-modulering med JAG1
eller JICD kunde ske via AP-1-transkriptionskomplexet. I detta avseende fann vi att i
Caski-cellinjen (HPV 16) sker transkriptionsmoduleringen av LCR via AP-1. Vi
bestämde vidare interaktionen mellan JAG1 och c-Jun-proteinet, vilket är ett
väsentligt element i AP-1-komplexet.

JAG1 processeras i livmoderhalscancer celler
Vi utförde WB-analys av endogent protein från livmoderhalscancercellinjerna Hacat,
C33A, Caski, Siha och Hela, och använde JAG1-antikroppen upp mot den C-terminala
ändan av JAG1, som känner igen alla cytoplasmiska former av proteinet. I figur 9A
visar vi uttrycket för JAG1 (180 kDa) och runt 25 och 20 kDa finns det band som
motsvarar CTF och JICD. Som rapporterats av LaVoie et al. (2003) motsvarar CTF
det JAG1-protein som saknar ECD på grund av klyvningen som medieras av
metalloproteaser ADAM17 (LaVoie & Selkoe, 2003). CTF är substratet för γ-sekretas
76

klyvning (Liebler et al., 2012). Observera att våra resultat beträffande uttryck av FL
JAG1 i livmoderhalscancercellinjer överensstämmer med tidigare rapporter
(Veeraraghavalu et al., 2004), som nämner att JAG1 uttrycks starkt i Caski-celler.
Närvaron av CTF och JICD är också högre i denna cellinje jämfört med andra
livmoderhalscancercellinjer.

JAG1 klyvs av γ-sekretas i livmoderhalscancer celler
För att ta reda på om JAG1 klyvs av γ-sekretas i livmoderhalscancerceller,
behandlades cellerna med DAPT, som är en γ-sekretasinhibitor och immunblottades
med en antikropp som höjdes mot den C-terminala svansen av JAG1, vilket kände
igen alla isoformer JAG1. I figur 10 representerar banden på vänster sida celler utan
DAPT-behandling, och till höger representerar banden celler behandlade med DAPT.
CTF är cirka 25 kDa. Under tiden är JICD 20 kDa; skillnaden i storlek är inte
anmärkningsvärd men tillräckligt för att kunna separeras från varandra.
Hacat- och Caski-celler förlora den intracellulära delen efter γ-sekretashämmare.
Sammanfattningsvis indikerar dessa resultat att behandlingen av JAG1-liganden
kräver y-sekretasaktivitet och att behandlingen sker genom samma mekanism som
Notch bearbetas.

Kloning av den intracellulära domänen för JAG1
För att kunna uttrycka JICD-proteinet, som är cirka 370 baspar var vi först tvungna att
klona det in i vår pcDNA3.1 (+) ryggrad. JICD- och JAG1-proteinet var taggat med
en HIS-domän vid N-terminalen. När detta väl lyckades transformerades
konstruktionen till DH5a-kompetenta celler och vi isolerade plasmiden från positiva
kolonier (figur 11).
När vi transfekterade C33A-celler, som normalt har ett litet uttryck för JAG1 (figur
9), med vår plasmid, och kunde se både FL och JICD med samma antikropp som
tidigare, kunde vi bevisa att kloning var framgångsrik (figur 12) . Storlekarna som ses
i de FL JAG1-transfekterade cellerna motsvarar 180 kDa-storleken på proteinet, och

77

de JICD-transfekterade cellerna visar ett band med 20 kDa-storleken, vilket är den
förväntade storleken på ICD för JAG1.

JAG1 och JICD modulerar aktiviteten för LCR i HPV
Det har visats att AP-1 kan moduleras av JAG1. De olika varianterna av HPV har olika
antal av AP-1 bindningsställen på LCR (figur 3) (O'Connor et al., 1996) (Steger &
Corbach, 1997). För att kunna avgöra om JAG1 och JICD kan modulera LCRaktiviteten i livmoderhalscancerceller transfekterade vi våra konstrukter i
livmoderhalscancercellinjerna: Hacat (spontant odödliggjorda humana keratinocyter),
C33A (skivepitelcervikal karcinom, HPV-negativ), Caski (skivepitelcancer, HPV16integrerat genom samt relaterade sekvenser till HPV18), Siha (skivepitelcancer,
integrerat HPV16-genom, 1 till 2 kopior per cell) och Hela (cervikal adenokarcinom,
HPV18-positiv).
I Hacat, som är HPV-negativt, är den basala aktiviteten för LCR18 den högsta av alla,
och det verkar som om överuttryck av JAG1 och JICD minskar LCR: s aktivitet.
Motsatsen händer i LCR16 med JICD, där uttrycket ökas något (figur 13).
I C33A-celler, som också är HPV-negativa, överexpressionen av JAG1 och JICD
verkar inte ha någon effekt på aktiviteten hos HPV16 LCR. Under tiden, när JAG1
överuttrycks, kan en ökning av HPV18 LCR observeras.
I Caski-celler, som har integrerat HPV16-genom och relaterade sekvenser till HPV18,
ökar LCR16-aktiviteten tydligt vid överuttryck av JAG1; medan när JICD
överuttrycks minskar aktiviteten betydligt. Aktiviteten för HPV18 LCR ökar
signifikant när JAG1 är överuttryckt och minskar signifikant när JICD är överuttryckt.
I Siha-celler, som är HPV16-positiva, är aktiviteten för LCR16 mycket lågt och
påverkas inte av uttrycket av JAG1 eller JICD. Tvärtom vid överuttryck av JAG1
främjas signifikant aktiviteten för HPV LCR18. I Hela-celler, som är den enda
HPV18-positiva celltypen i dessa experiment och enda cellinjen som härrör från
adenokarcinom, minskar överuttrycket av JAG1 aktiviteten för LCR16, och

78

förändringarna i JICD är inte signifikanta. Även om dess autologa LCR (HPV18) inte
påverkas av JAG1 eller JICD.

Moduleringen av LCR med JAG1 och JICD är dosberoende
Kontroversiella resultat om deltagandet av Notch i livmoderhalscancer har tidigare
rapporterats (Talora et al., 2002) (Talora et al., 2005) (Henken et al., 2012). Henken
et al. (2012) visar att effekten på Notch-transkriptionsreglering över HPV är
dosberoende. Således letade vi efter en dosberoende effekt av JAG1 och JICD i
livmoderhalscancercellinjer. Resultat i figur 14 visar moduleringen av HPV16 och
HPV18 LCR under låg koncentration av JAG1 och JICD. De första erhållna resultaten
(figur 13) gjordes med 800 ng JAG1 och JICD, under tiden i figur 14 gjordes
aktiviteten hos de autologa LCR: erna i Caski, Siha och Hela-celler med lågt uttryck
av JAG1 och JICD (100 ng).
Som det kan observeras finns det ingen effekt när man sänker koncentrationen av
JAG1 i Caski-celler (figur 14). Även om JICD ändras från att undertrycka till att
främja aktiviteten hos HPV LCR16. I Siha-celler hade den höga nivån av JAG1 och
JICD ingen effekt (figur 14), men låga koncentrationer av proteinerna främjar
aktiviteten hos HPV16 LCR. Slutligen, i Hela-celler som inte heller svarade på höga
koncentrationer av JAG1 eller JICD, hade låga koncentrationer ingen uppenbar effekt
över HPV18 LCR-aktiviteten.
Dessa resultat stöder våra tidigare observationer att HPV18 LCR inte svarar på JAG1
eller JICD i transformerat tillstånd. Det är anmärkningsvärt att Talora et al. (2002)
visar att NICD-uttryck modulerar HPV-transkription i Hela-celler, men inte i Sihaeller Caski-celler. (Talora et al., 2002). Dessa resultat ger upphov till en diskussion
om möjligheten att andra mekanismer som skiljer sig från Notch är inblandade.

Moduleringen av HPV LCR i Caski-celler är beroende av AP-1-aktivitet
AP-1-komplexet är en viktig faktor i viralt onkogenuttryck (de Marco et al., 2012).
Epstein Barr-viruset har exempelvis AP-1-responsiva sekvenser på dess genom
79

(Baumann et al., 1998), och i fallet med HPV16 och HPV18 presenterar de också AP1-bindningsställen på sitt genom. Aktiveringen av AP-1 kan induceras kemiskt av
Phorbol-estrar (TPA). Detta främjar AP-1-bindning till TPA-svarselementet (TRE).
För att bestämma effekterna av AP-1-transkriptionsaktivitet över LCR under
expression av JAG1 och JICD, behandlades celler med TPA och luciferasreportergenen mättes.
I figur 15 jämför vi transkriptionsaktiviteten för icke-behandlade celler transfekterade
med JAG1 eller JICD mot celler transfekterade med samma konstrukter och
behandlade med TPA i 24 timmar. I Caski-celler hade TPA-behandling ingen effekt
på kontrolltillståndet. Men TPA-behandlingen motverkar ökningen av HPV16 LCRaktivitet inducerad av JAG1-transfekterade celler; under tiden, i JICD-transfekterade
celler, ökar TPA-behandlingen LCR-aktivitet men inte till kontrollnivåerna och inte
signifikant. Dessa resultat pekar på en reglering av HPV LCR16-aktivitet av JAG1
och JICD på ett sätt som påverkas av AP-1-aktivitet.
I Siha-celler ökar förhållandena transfekterade endast med den autologa LCR16 och
pCDNA3.1 (+) TPA-behandlingen transkriptionsaktiviteten med nästan 80%,
liknande beteende kan observeras i JAG1- och JICD-överuttryck. Föreslår att JAG1
och JICD inte har någon effekt på LCR, inte heller en relation till AP-1-aktiviteten.
Slutligen minskar behandlingen med TPA i Hela-celler transkriptionen av den
autologa HPV18 LCR i kontrolltillståndet liksom vid överuttryck av JAG1 och JICD,
vilket tyder på att dessa proteiner inte är involverade i regleringen av LCR.

AP-1-transkriptionsfaktorkomplexblottar i livmoderhalscancer-celler
Det finns bevis som stöder att förändringar i AP-1-komplexkompositionen kan
påverka tumörgeniciteten hos cellerna. Henken et al. (2012) hävdar att hög Notchexpression förändrar AP-1-kompositionen från c-Jun / c-Fos-homodimer till den icketumöriska c-Jun / c-Fra-formen (Henken et al., 2012). Vi utvärderade därefter
uttrycket av c-Jun, c-Fos och c-Fra och genomförde densitometri-analys.

80

Som observerats i figur 16 är uttrycket av c-Jun ungefär detsamma i alla studerade
cellinjer. Detta förväntas eftersom c-Jun är huvudkomponenten i AP-1-komplexet,
vilket innebär att det alltid finns som antingen en homodimer eller heterodimer med
antingen c-Fos eller c-Fra. I fallet med c-Fos är det anmärkningsvärt det faktum att
Caski-celler presenterar en mycket låg mängd protein. Det har tidigare rapporterats att
Caski- och Siha-celler har en integration på deras c-Fos-kodande region, så de har ett
lägre uttryck för denna komponent. Även om uttrycket av c-Fos i våra Siha-celler är
signifikant högre än Caski. C-Fra uttrycks på liknande sätt i alla de transformerade
cellinjerna, och ett högre uttryck observerades i den icke-tumörgena cellinjen Hacat.
Ett förväntat resultat eftersom det är känt att c-Jun / c-Fra-dimer är relaterat till icketumörgeniskt beteende (Henken et al., 2012).
Skillnaderna i AP-1-komponenterna som observerats i våra cellinjer kan också
redovisas för skillnaderna vi observerade i kontrollaktiviteten för HPV16, HPV18
LCR (figur 13) Det är intressant att vi kan observera en effekt av JAG1 och JICDöveruttryck på LCR-aktivitet i Caski-celler, vilket visar sig vara de med mindre c-Fos.

JICD minskar proliferation av Caski- och Hela-celler
Efter att ha visat att JAG1 och JICD kan modulera LCR och att hans effekt är
dosberoende och också beroende på AP-1-aktivitet, fortsatte vi med att undersöka CCcellernas spridningshastigheter. pCDNA3.1 (+) och den autologa LCR till cellinjen
användes som en kontroll och JAG1 och JICD överuttrycktes i systemet. Resultaten i
figur 15 visar att i Caski-celler minskar JICD proliferationen jämfört med kontrollen.
Spridning av JAG1-transfekterade celler var den högsta, men inte signifikant högre än
den tomma vektorn. Spridningen minskade också i Hela-celler transfekterade med
JICD jämfört med pCDNA3.1 (+) -tillståndet. När dessa celler transfekterades med
JAG1 orsakade det en liten minskning av proliferation jämfört med kontrollen, även
om den inte var signifikant.
Dessa resultat bekräftar våra observationer av LCR-modulering med JAG1 och JICD,
eftersom proliferationen under JICD-uttryck i Caski-celler minskar, liksom
transkriptionsaktiviteten (figur 13). Således skulle det vara nödvändigt att utvärdera

81

uttrycket av E6 och E7 under samma förhållanden. Att utvärdera målen för de virala
onkoproteinerna p53 och pRB skulle också vara intressant. Resultaten som presenteras
här pekar på en skyddande effekt av JICD mot HPV-infektion.

JAG1 binder till c-Jun
Genom att göra Co-IP bekräftade vi en interaktion mellan c-Jun och JAG1 i
livmoderhalscancerceller (figur 19 & 20). I input samplen kan man se ett band med
motsvarande storlek för c-Jun (43, 48 kDa) och även i de precipiterade samplen. Vi
kunde bara observera en interaktion mellan c-Jun och JAG1 i Caski-celler. Denna
interaktion kan förklara den modulering som observerats över LCR-aktivitet under
JAG1-uttryck. Även om vi inte vet om interaktionen är exklusiv för JICD eller
JAG1FL. För att kolla om interaktionen är exklusiv för endera JAG1 eller JICD,
överuttryckte vi JAG1 och JICD i C33A-cellinjen som har ett lågt uttryck för endogen
JAG1. I figur 22 observerar vi att c-Jun binder till båda formerna av JAG1. Det är
viktigt att nämna att resultaten behöver behandlas ytterligare eftersom C33A inte är
negativt för endogent JAG1-uttryck, så bakgrundsnivåerna för proteinet kan maskera
observationerna. Detta är avgörande eftersom LaVoie & Selkoe. (2003) nämner att
moduleringen av AP-1 är beroende av JICD (LaVoie & Selkoe., 2002) Tidigare arbete
har föreslagit interaktionen mellan JICD och AP-1 (Hye Jin Lee et al., 2015).
Interaktionen mellan JICD och Fe65 kan främja kärntranslokalisering av JICD och
bindning till AP-1-komplexet. Med de resultat som erhållits här kan vi inte dra
slutsatsen om JICD binder direkt till c-Jun eller som en del av ett komplex. Vi har
heller inga bevis där denna interaktion i cellen sker, en trolig hypotes skulle vara att
c-Jun och JICD interagerar i cytoplasman som skulle blockera kärntranslokationen av
c-Jun, vilket minskar LCR-aktiviteten.
Ytterligare förtydliganden om deltagande av JAG1 och dess klyvda form om viral
transkriptionsreglering måste göras. Här presenterar vi bevis som tyder på att JAG1
klyvs i livmoderhalscancercellinjer. Överuttrycket av JAG1 och JICD modulerar
aktiviteten för HPV16 och HPV18 LCR beroende på celltyp, och JAG1 kan binda till
c-Jun.

82

